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No Name Age Sex Occu
IP/
OP DOI Drugs
Wt
(kg)
Ht
(m) BMI SBP DBP FBS HbA1C S.Mg U-Pro Urea S.C LP NPDR PR
1 THANGAM 51 F S OP 5 OHA 45 1.39 23.29 126 82 141 8 1.6 <300 36 1 N N Nil
2 THAYEE 58 F S OP 6 OHA 56 1.55 23.31 130 92 136 7 1.6 >300 35 1.1 HL N NIL
3 SUSEELA 49 F NS OP 3 OHA 78 1.58 31.24 140 80 128 6.5 1.7 <300 35 1 N N NIL
4 MEENA 43 F NS OP 1 OHA 64 1.62 24.39 126 84 118 6 1.8 <300 28 1.2 HL N NIL
5 PANJALI 60 F S OP 10 OHA 65 1.57 26.37 156 90 130 8 1.6 >300 36 1.2 HL P NIL
6 RANI 57 F S OP 9 OHA 75 1.52 32.46 138 90 142 9 1.6 <300 34 1.2 HL P NIL
7 KANNAN 65 M S OP 8 OHA 76 1.64 29.74 150 100 136 9 1.5 >300 40 1.8 HL N NIL
8 GOPAL 65 M NS OP 10 OHA+INJ 76 1.58 32.89 140 92 126 7 1.6 <300 36 1 HL P NIL
9 JAYARAM 69 M S OP 6 OHA 80 1.64 10.02 140 90 132 8 1.6 <300 28 1.1 HL N NIL
10 GANGA 61 F S OP 5 OHA 65 1.42 32.23 140 90 128 10 1.6 <300 36 1.2 HL N NIL
11 AMUDHA 50 F NS OP 3 OHA 61 1.6 23.82 130 90 116 7 1.7 <300 36 1.2 N N NIL
12 SUNDHARI 74 F S OP 12 OHA 60 1.63 22.58 140 90 122 7 1.9 <300 32 1.2 N N NIL
13 VIJAYA 42 F NS OP 2 OHA 75 1.64 27.81 130 80 126 7 1.8 <300 36 1 N N NIL
14 BHAI 45 M NS OP 3 OHA 95 1.71 32.49 140 90 132 8 1.8 <300 36 1.2 HL N NIL
15 CHANDRA 39 F NS OP 1 OHA 50 1.52 21.64 130 80 120 6.5 2 <300 32 1.1 N N NIL
16 THAMBI 61 M S OP 8 OHA 59 1.65 25.71 126 92 126 9 1.7 <300 36 1 N P NIL
17 SURYA 55 F NS IP 6 OHA 65 1.7 26.1 122 86 135 10 1.5 >300 36 1.2 N N NIL
18 BANU 59 F NS OP 8 OHA 67 1.49 30.17 130 82 140 11 1.6 >300 38 1.4 N N NIL
19 DURAI 64 M NS OP 10 OHA 65 1.42 32.25 140 90 130 12 1.4 >300 36 1.2 HL N NIL
20 MANI 52 M NS OP 6 OHA 79 1.72 27.33 140 90 136 10.5 1.6 <300 35 1 N N NIL
21 RAJENDREN 58 M NS OP 8 OHA 62 1.58 24.83 138 92 219 10 1.7 <300 36 1.2 N N NIL
22 CHELLAM 75 M S OP 10 OHA 56 1.62 21.21 150 90 225 9 1.6 >300 38 1.2 N P NIL
23 JANAKI 54 F NS OP 4 OHA 66 1.5 29.33 152 90 223 11 1.6 >300 38 1.2 N P NIL
24 RUBY 60 F NS OP 10 OHA 62 1.6 24.21 100 80 98 6 1.9 <300 32 0.9 N N NIL
25 CHANDRA 67 F NS OP 6 OHA 68 1.7 28.52 128 90 83 6 1.6 <300 30 1 N N NIL
26 MANO 38 M NS OP 1 OHA 86 1.65 31.59 130 80 240 9 1.6 <300 29 1.2 N N NIL
27 RAJU 64 M NS OP 6 OHA 72 1.78 26.37 150 90 180 10 1.6 >300 40 1 N N NIL
28 PAKARI 59 M S OP 5 OHA 78 1.65 28 150 90 250 11 1.5 <300 42 2.1 N P NIL
29 SAMI 64 M NS OP 7 OHA 82 1.68 29 138 86 164 9 1.7 <300 30 1.2 N N NIL
30 THIRU 50 M NS IP 3 OHA 65 1.69 32 140 90 118 7 1.9 <300 30 1.2 N N NIL
31 RAMESH 38 M NS OP 3 OHA+INJ 68 1.65 23 120 80 148 10 1.5 >300 40 2.5 N P NIL
32 PANDU 42 M NS OP 5 OHA+INJ 70 1.78 22 120 80 98 6.5 1.8 <300 32 1 N N NIL
33 PAVUNU 67 F S OP 5 OHA 68 1.53 29.5 140 90 145 11 1.6 >300 36 1.1 N N NIL
34 BEEBEE 58 F NS OP 8 OHA+INJ 69 1.55 28.72 138 80 185 9 1.6 >300 36 1.2 N P NIL
35 USMAN 63 M NS OP 11 OHA 72 1.61 27.78 130 80 165 11 1.7 >300 38 1.2 N P NIL
36 LATHA 60 F NS OP 9 OHA+INJ 69 1.58 27.65 140 90 163 9 1.7 >300 36 1.1 N N NIL
37 RANI 50 M NS OP 6 OHA 75 1.65 27.55 120 90 154 9 1.8 <300 32 1 N N NIL
38 MANJULA 49 F NS OP 3 OHA 64 1.75 20.09 120 80 100 11 1.6 <300 30 1 N N NIL
39 RAMAN 61 M NS IP 10 OHA 73 1.71 24.96 136 92 168 10 1.7 >300 38 1.2 HL P NIL
40 BALA 57 M NS OP 6 OHA 75 1.78 23.67 128 96 115 6 1.8 <300 32 1.2 N N NIL
41 MOHAN 56 M NS OP 6 OHA 75 1.48 34.24 130 80 263 11 1.6 >300 36 1.2 HL P NIL
42 KAMALA 45 F NS OP 5 OHA 68 1.63 25.59 134 83 111 9 1.8 <300 34 1 HL N NIL
43 KASTHURI 48 F NS OP 3 OHA 70 1.56 28.76 130 80 144 9 1.7 >300 36 1.6 HL N NIL
44 SUMAN 69 M NS OP 11 OHA 69 1.56 27.99 110 82 121 8 1.8 <300 32 1.2 N N NIL
45 KATTAN 52 M NS OP 6 OHA&INJ 78 1.58 34.67 110 78 148 9 1.6 >300 36 1.2 HL N NIL
46 PICHAI 70 M S OP 10 OHA 70 1.69 24.51 148 82 105 6 1.7 <300 32 1 N N NIL
47 NEELA 71 F S OP 9 OHA 65 1.55 27.06 136 88 128 7.5 2 <300 36 1 N P NIL
48 THULASI 48 F NS OP 5 OHA 64 1.67 22.95 140 78 132 8 1.9 <300 34 1.1 N N NIL
49 ARUMUGAM 50 M NS IP 5 OHA&INJ 76 1.69 26.61 130 82 152 9 1.7 >300 36 1.2 HL NI NIL
50 MURUGAN 48 M NS OP 4 OHA 85 1.71 29.07 140 94 252 9.5 1.6 <300 35 1.1 HL P NIL
51 KRISHNAN 55 M NS OP 5 OHA 80 1.75 26.12 132 82 152 10 1.9 <300 33 1 N N NIL
52 BABU 38 M NS OP 1 OHA 79 1.8 24.38 128 88 150 8.5 1.9 <300 34 1.1 N N NIL
53 THAYALAN 39 M NS OP 1 OHA 70 1.74 23.12 124 80 126 8 1.7 <300 36 1 N N NIL
54 KALA 40 F NS OP 4 OHA 64 1.61 24.69 110 86 105 6.5 1.9 <300 34 1.1 N N NIL
55 MURTHY 54 M NS OP 8 OHA 73 1.78 23.04 112 82 121 7 1.6 >300 30 1.2 N N NIL
56 SASIKALA 41 F NS OP 1 OHA 65 1.63 24.4 140 90 115 8 2 <300 36 1.1 N N NIL
57 MUTHU 58 M NS OP 7 OHA 74 1.74 24.1 130 80 110 6 2 <300 35 1 N N NIL
58 RAJA 54 M NS IP 4 OHA 72 1.69 25.21 140 82 148 10 1.6 >300 40 1.8 HL P NIL
59 SELVAM 52 M NS OP 3 OHA 83 1.84 24.52 110 82 96 6 2.1 <300 36 1.1 N N NIL
60 SHEELA 58 F NS OP 8 OHA&INJ 58 1.5 25.78 120 90 92 6 2 <300 34 1 N N NIL
61 JAMEELA 52 F NS OP 6 OHA 100 1.55 41.62 140 90 223 10 1.6 >300 36 1.2 N N NIL
62 RUPA 49 F NS OP 9 OHA+INJ 95 1.65 34.89 140 90 245 10 1.6 >300 40 2 HL P NIL
63 ELLAMMAL 63 F S OP 9 OHA 65 1.51 28.51 140 80 189 10 1.6 >300 36 1 N N NIL
64 THIYAGU 70 M S OP 10 OHA 67 1.76 21.63 150 90 90 6.5 1.8 <300 28 1.2 N N NIL
65 KILLIAMMAL 69 F S OP 9 OHA+INJ 64 1.6 25 150 90 98 6 1.8 <300 28 1.2 N N NIL
66 NADHU 41 M NS OP 6 OHA 72 1.75 23.51 30 80 116 6.7 1.7 <300 32 1 N N NIL
67 PUSHA 59 F NS OP 6 OHA+INJ 69 1.57 27.99 150 90 320 11 1.5 >300 36 1.2 N N NIL
68 MURALI 51 M NS OP 5 OHA 69 1.69 24.16 140 90 236 10 1.7 >300 30 0.9 N P NIL
69 LAKSHMI 59 F NS OP 6 OHA+INJ 69 1.57 27.99 150 90 220 11 1.6 >300 38 1.2 N P NIL
70 SUNDHARI 61 F S OP 10 OHA 70 1.55 29.14 140 80 200 11 1.6 >300 30 1.7 N N NIL
71 MUNIAMMAL 65 F S IP 12 OHA 75 1.52 32.46 130 90 187 9 1.6 <300 26 1 N N Nil
72 VARADHAN 75 M S OP 15 OHA&INJ 69 1.68 24.45 140 90 210 9 1.6 >300 36 1.2 N NI NIL
73 SARASU 68 F NS OP 10 OHA 65 1.76 20.98 120 86 188 8 1.6 >300 36 1.2 N P NIL
74 MANIMEGALAI 67 F NS OP 7 OHA 62 1.58 24.84 150 90 200 11 1.5 >300 36 1.2 N P NIL
75 URLAMILA 48 F NS OP 5 OHA 68 1.6 26.54 140 90 135 7 1.8 <300 30.8 1.2 HL P NIL
76 BRINTHA 40 F NS OP 2 OHA+INJ 65 1.65 23.88 130 80 98 6 2 <300 32 1 N N NIL
77 BANU 39 F NS OP 1 OHA 60 1.62 22.86 130 90 90 6.5 2 <300 26 1 N N NIL
78 MEERA 45 F NS OP 3 OHA 65 1.59 22.79 126 86 101 7 1.7 <300 28 0.8 N N NIL
79 JAYATHI 40 F NS OP 2 OHA 60 1.63 22.58 128 78 93 6.5 2 <300 30 1 N N NIL
80 KAMATCHI 58 F S IP 5 OHA 70 1.66 25.4 130 90 98 6 1.6 <300 32 1 N N NIL
81 POOGKODI 55 F NS OP 3 OHA 65 1.59 25.71 128 78 105 7 2 <300 28 1 N N NIL
82 AMMU 45 F NS OP 2 OHA 66 1.58 26.44 126 82 110 8 2 <300 27 1 N N NIL
83 SURYA 52 M NS OP 6 OHA&INJ 68 1.52 29.43 136 88 112 8 1.7 >300 36 1.2 HL P NIL
84 VEERAN 72 M S OP 10 OHA 65 1.71 22.23 148 88 115 8.5 1.7 <300 37 1.2 N N NIL
85 RATHINAM 78 M S OP 12 OHA 78 1.65 25.86 146 90 105 7 1.7 <300 36 1.2 N N NIL
86 GOMATHI 69 F S OP 12 OHA 65 1.54 27.41 150 100 185 10 1.6 >300 36 1.2 N P NIL
87 SEETHA 65 F S OP 9 OHA 59 1.59 23.34 148 90 122 7 1.8 <300 30 1.2 N N NIL
88 MANI 41 M NS IP 1 OHA 75 1.72 22.35 120 8 110 77 1.7 <300 34 1 N N NIL
89 SRINIVAS 40 M NS OP 1 OHA 70 1.65 25.71 116 78 126 8 1.9 >300 32 1 HL N NIL
90 MOHAN RAJ 52 M NS OP 4 OHA 65 1.66 23.79 126 70 114 7 1.6 <300 32 1 N N NIL
91 DHANAM 55 M NS OP 5 OHA 56 1.67 20.08 130 80 96 6.5 2 <300 36 1.2 N N NIL
92 THIRUPATHI 60 M NS OP 6 OHA 58 1.6 23.39 150 90 89 6.6 2 <300 28 1 N N NIL
93 ARUL 42 M NS OP 3 OHA 65 1.71 25.97 140 80 100 7 1.9 <300 28 0.9 N N NIL
94 NARESH 48 M NS OP 5 OHA&INJ 70 1.73 27.6 136 80 109 7 1.8 <300 34 0.8 N N NIL
95 DILLI RANI 63 F S OP 10 OHA 60 1.52 29.22 140 90 96 7 1.6 <300 36 0.7 N N NIL
96 SIVAGAMI 65 F S OP 10 OHA 65 1.55 26.3 150 100 256 7 1.8 <300 39 1 N N NIL
97 ANJALI 67 F S IP 10 OHA 64 1.48 25.39 140 96 101 6 1.9 <300 31 1.2 N N NIL
98 SURESH 48 M NS OP 5 OHA&INJ 64 1.56 26.3 130 80 156 6 2 <300 30 1.1 N N NIL
99 MALAR 58 F NS OP 8 OHA 65 1.6 25.39 128 86 181 6.4 1.8 <300 28 0.9 N N NIL
100 KUMAR 52 M NS OP 5 OHA 73 1.68 25.86 148 90 108 6.4 1.9 <300 30 1 N N NIL
101 LEELA 55 F NS OP 4 OHA 67 1.54 28.25 130 84 121 7 1.7 >300 36 N N NIL
102 SHANMUGAM 59 M NS OP 7 OHA 72 1.63 27.1 128 80 111 6.5 1.8 <300 32 N N NIL
103 RAVI 69 M S OP 9 OHA 70 1.64 26.03 140 86 138 9 1.9 <300 34 N N NIL
104 MANNU 66 M NS OP 7 OHA 67 1.7 23.18 138 90 120 7 2 <300 30 N N NIL
105 SIVA 45 M NS OP 3 OHA 79 1.71 27.02 140 90 118 7 2 <300 32 N N NIL
106 RAMU 56 M NS OP 4 OHA 60 1.68 21.26 146 98 100 6.5 1.9 <300 31 N N NIL
107 VADAMALAI 69 M S OP 11 OHA 69 1.74 22.79 120 82 132 8 1.7 >300 32 HL P NIL
108 DHAMU 56 M NS IP 3 OHA 73 1.58 29.24 130 80 125 7.5 1.9 <300 34 N N NIL
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ABSTRACT:
A high prevalence of magnesium deficiency in found in diabetes.
Magnesium deficiency has a negative impact on glucose homeostasis
and insulin sensitivity in Type 2 diabetic patients as well as on the
evolution of complication such as retinopathy, neuropathy, nephropathy
and arterial atherosclerosis.
The aim of this study is to estimate the prevalence of hypomagnesemia
in patients with type 2 diabetes mellitus and its correlations with micro
and macrovascular complications of diabetes – retinopathy,
nephropathy, neuropathy and ischemic heart disease.
Patients with type 2 diabetes admitted in Chengalpaattu Medical
Hospital, Chengalpattu over a period of one year between 1st September
2013 to 30th September 2014 formed the study population. The sample
size was 100 patients.
The study revealed that prevalence of hypomagnesemia in study subjects
was 31%. Sex, age and duration of diabetes were not significant
predictors of serum magnesium. Significant association was found
between hypomagnesemia and diabetic retinopathy. Significant
correlations were found neither with other diabetic microangiopathies
nor with comorbitities such as ischemic heart disease and hypertension.
Low serum magnesium concentrations are common in type2 diabetics.
Magnesium deficiency is conclusively associated with diabetic
retinopathy.
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STUDY ON SERUM MAGNESIUM LEVEL IN PATIENTS WITH
TYPE2 DIABETES AND ITS CORRELATION WITH
DIABETICRETINOPATHY AND NEPHROPATHY
INTRODUCTION:
Diabetes melitus, commonly called as diabetes mellitus, is a group of
metabolic disorder of chronic duration  in which the person have increase blood
glucose (blood sugar), either fasting  and/or postprandialiy. It caused by either
insulin secretion is not sufficient or the body's cells do not respond properly to
insulin, or both. It  is one of the cause for leading  mortality  mortality in
developing countries.
The chronic state hyperglycemia  leads term damage, dysfunction and
failure  various system  of our body particularly the eyes, kidneys, nerves, heart
and blood vessels. Most of people suffering from diabetes fall into two major
categories, IDDM or type 1 DM: those having minimal or no endogenous
secretion of insulin.. Type 2 or NIDDM: endogenous insulin secretion
capacity is retained  but they may have either resistance to insulin action and
an inadequate compensatory insulin secretion response. There is increasing
incidence of among young people, reproductive age group due to various factor.
The risk of developing complication is more and growing among the patients
with type2 diabetes mellitus .The disease has become a major public health
issue causing huge economic loss in developing and well developed nation.
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Impairment of insulin secretion and defects in insulin action can present
frequently in the same patient. Several vitamins and minerals act as cofactors in
the enzyme reaction regulated by insulin. Deficiencies of certain vitamins and
minerals such as potassium, magnesium, zinc and chromium may increase
carbohydrate intolerance. Of these, the need for potassium or magnesium
replacement is relatively easy to detect based on low serum levels.
Magnesium act as a cofactor in both glucose transport mechanism of the
cell membranes and for various intracellular enzymes involved in carbohydrate
oxidation. The concentrations of magnesium in serum of healthy people are
remarkably constant, whereas 25-39% of diabetics have low concentrations of
serum magnesium. The reasons for magnesium deficiency in diabetes may.
include increased urinary excretion, lower level of intake , or decreased
absorption of magnesium compared to healthy individuals
.
Magnesium
depletion has a negative impact on glucose homeostasis and insulin sensitivity
in patients with type 2 diabetes, it has reported that people  with diabetes are
often obese and their  dietary intake of magnesium level was low. It may also
due to increased urinary loss see normally in diabetic people involved in the
evolution of complications such as retinopathy, arterial atherosclerosis11 and
nephropathy
.
Moreover, low serum magnesium is a strong self regulating
predictor in the development of type 2 diabetes. The present study was
undertaken with an aim to estimate prevalence of hypomagnesaemia in patients
with type 2 DM and to correlate the serum  magnesium concentrations with
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micro and macro vascular complications  of diabetes-retinopathy, nephropathy
and ischemic heart disease and autonomic neuropathy.
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OBJECTIVES
This study is aimed at,
1.Estimating the serum magnesium concentrations in patients with
Type 2 Diabetes mellitus.
2.Correlating serum magnesium concentrations with complication like
diabetic retinopathyand diabetic nephropathy.
3.Correlation serum level magnesium level with blood sugar level
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REVIEW OF LITERATURE
DIABETES MELLITUS
It comprises a group of metabolic disorders that share the
common feature of increased blood sugar level. Several different types are
present and are caused by a interaction of genetics and environmental factors
Excessive intake of high calorie, food, sedentary life style and obesity all these
increase the risk of diabetes. The word diabetes derived from Greek word
meaning to pass through or siphon meaning excessive urination associated with
the disease and mellitus means like honey like reflecting sweet smell associated
with urination. Increase resistance of insulin to peripheral tissue, defective
insulin secretion in response to glucose and glucose over production are three
important feature in the development of the disease. It is the leading cause of
morbidity and mortality in the future.
HISTORICAL ASPECTS
This disease was first recognized in ancient times, but its history has
been evolved over times and is characterized by numerous cycles of discovery,
neglect and rediscovery. Its history can be divided into four major periods that
reflect different phases in the understanding and management of the disease.
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The ‘ANCIENT’ period witnessed the first clinical descriptions of diabetes and
complications.
1. From 1600 to 1800 years it has been termed the ‘DIAGNOSTIC’
period, as this disorder was then considered as a separate entity.
2. The middle and late 19th century may be regarded as the first
‘EXPERIMENTAL’ period, characterized by gluco-regulatory role of pancreas
has become clear and the disturbances in biochemical diabetes were initially
established
.
3. The 20th century has seen a dramatic increase in knowledge and
awareness about diabetes. Finally, the discovery of insulin in 1921-22 has had
profound scientific, clinical and social consequences.
Some key developments in scientific and clinical understanding of diabetes may
be summarized as follows:
 Ancient Egyptian papyrus described Polyuric states, clinically resembles
diabetes mellitus and discovered by George Ebers as early as 1550 BC.
 Indian physicians observed  sweetness of diabetic urine in the 5th and
6th century AD by the (Sushruta and Charaka) and Thomas Willis. in
the 17th century.
 John Rollo was first used the term ‘Diabetes mellitus’ meaning honey
taste of urine,  in the late 1800.
 Matthew Dobson In 1776 postulated that  diabetes was a systemic
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condition rather than a disorder function in kidneys.
 During the mid to late 19th century, Claude Bernard has stated that liver
store   the  glucose as glycogen and causes hyperglycemia.
 Oskar Minkowski and Josef Von Mering discovered in 1889, that total
pancreatectomy causes diabetes in animal.
 During 1869,Paul Langerhans, a medical student freo Berlin- some tissue
clumps scattered throughout the pancreases which was later known as
islets of Langerhans.
 Edouard Lagussee pointed out that they might produce secretions having
the role of regulation in digestion.
 Nicolas Paulesco and George Zuelzer extracted the impure hypoglycemic
extract from the pancreas.
 In 1921,Frederick G. Banting, Charles H. Best, James B. Collip and J.J.R.
Macleod discovered  first Insulin at the University of Toronto.
 In January 1922, insulin was separated from pancreas and experimented
that it has the power to lower blood glucose levels in pancreatectomised
dogs. Later tested in a human diabetic (Leonard Thompson).
Some of the significant advances in understanding the diabetes and
metabolism are :
 Elucidation insulin’s three dimensional structure by Dorothy Hodgkin in
1969 and sequencing of insulin by Frederick Sanger in 1955.
 The measurement of insulin concentration using the first radio
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immunoassay, by Solomon Berson and Rosalyn Yalow in 1959.
 Separation of proinsulin by Donald Steiner’s group in Recognition
and classification of specific insulin.
Major achievements in diabetes management is
 The development of long acting insulin preparations.
 Examination and validation of sulfonylureas.
 Use of biguanide (as a first therapeutic measure since 1957.
 Introduction strips suitable for self monitoring blood glucose in the late
1970’s.
 Strict glycemic control could slow or prevent the development of
diabetic microvascular complications.
 World diabetes day is being celebrated.
every year on 14th November since 1991. This day marks birthday of
in 2007. The colour indicates the sky that unites all nations.
The circle indicates the unity of the global diabetes community.
Figure1: Symbol of World Diabetes day
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 Slogan for this year is “Diabetes: protects our future” The key message are
 Easy choice  to make healthy food
 Right choice  for healthy eating
 Healthy eating starts with breakfast
Table:1.CLASSIFICATION OF DIABETES
Spectrum of glucose homeostasis and diabetes mellitus
Types of
Diabetes
Normal
tolerance
glucose
Hyperglycemia
Impaired
fasting
glucose or
impaired
glucose
tolerance
Diabetes mellitus
Not
insulin
required
Insulin
required
for
control
Insulin
required
for
survival
Type 1
Type 2
Other Other specific
specif types
Gestational
diabetes
Time( years)
FPG(mg/dl) <110 110-125 >126
<140 140-199 > 200
Table1: Classification of Diabetes
Classification based on etiology
I) Type 1 - caused by absolute insulin deficiency due to β-cell destruction
which may be due to idiopathic or immune related.
II) Type 2 diabetes- caused by insulin resistance with relative deficiency in
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insulin secretion or defect in insulin secretion.
III Specific types of diabetes
Due to mutation causing genetic defect :
1. MODY-1 due to Transcription factor HNF
2. MODY-2due to glucokinase
3. MODY-3 due to HNF1
4 MODY -4 due to Insulin promoter factor
5 MODY- 5.due to HNF – 1β
6. Neuro D1 (MODY 6)
7. Defect in Mitochondrial DNA
8. Defect in Proinsulin or insulin .
Due to genetic defect :
1.1Lipodystrophy syndromes.
1.2.Rabson-Mendenhall syndrome
1.3.Type A insulin resistance
1.4.Leprechaunism
Exocrine pancreatic diseases  like pancreatectomy pancreatitis, neoplasia,
hemochromatosis, cysticfibrosis, fibrocalculous pancreatopathy.
 Diseases of Endocrinesystem – Cushing’s syndrome,
pheochromocytoma, acromegaly,glucagonoma, somatostatinoma
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aldosteronoma and hyperthyroidism.
 Chemical or drug related – Vacor, pentamidine, thyroid hormone,
nicotinic acid, beta agonists, phenytoin, steroids diazoxide,
thiazides, protease inhibitors and clozapine, α– interferon.
 Infections –, cytomegalovirus ,rubella infection, coxsackie.
 Immune-mediated diabetes – “stiff person”syndrome, anti-insulin
receptor antibodies.
 Associated with other genetic syndromes: Laurence-moon-biedl
syndrome, Turner syndrome Wolfram syndrome, Down syndrome.
Klinefelter syndrome Friedreich ataxia etc
IV) Gestational diabetes mellitus (GDM):
PATHOGENESIS
Type 1- due to deficiency in insulin secretion caused by beta cell
destruction by autoimmune process. Interaction of genetic, immunological and
environmental factors. The susceptibility gene located in HLA DR3 andDR4
region on chr.6  Islet cell antibodies directing against  islet molecule
(GAD,insulin) are present, Environmental factor like viruses, drugs and bovine
milk protein .70-80% of beta cell to be destroyed for the disease to occur.
Type 2- diabetes mellitus is a heterogeneous group of disorders
represented by insulin resistance, decreased insulin secretion increased
production of glucose and disorder in the fat metabolism.(increased hepatic
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production of lipid and glucose).Insulin resistances syndrome-combination of
hyperlipidemia, hypertension and insulin resistance.
Metabolic defects in insulin action and/or secretion give rise to the
common feature of hyperglycemia in type 2 diabetes mellitus which are
different genetic origin.
IDDM and NIDDM are not in use now-a-days as type2 DM also need
insulin for management and control of hyperglycemia so the term NIDDM often
causes considerable confusion. Age factor is not a important criteria for the
classification. Though type 1 diabetes mellitus develops commonly before the
age of 30, the autoimmune beta cell destructive process can be occur at any age.
It is estimated that type 1 diabetes mellitus develop much earlier ,before age of
30 which constitute5-10%pooulation,auto immune destruction occur at any
age.. Similarly, type 2 diabetes mellitus mostly typically occur in individuals
with increasing age. However it can also affect the children, obese adolescents
in particular.
TYPE 1 DIABETES MELLITUS
Diabetes with immune mediation (Type 1A)
Accounts for only five to ten percent of those affected with
diabetes, arises from abnormality in a cell mediated and humoral system leads
to immune destruction of the islets of beta cells, autoantibodies to hormonal
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insulin, islet cell auto antibodies, autoantibodies to the tyrosine phosphatases
IA-2 and IA-2B, autoantibodies to GAD65. IA2/ICA512, Glutamic acid
decarboxylase (GAD65) are some of the markers for the disease  showing auto
immune activity.
Figure 2 : Factors involved in type 1 Diabetes Mellitus
When fasting hyperglycemia is  initially recognized ,one or usually
more of these auto antibodies are present in >90%patients. Most affected
individual have HLAA1*0301,HLADQB1*0302 andHLADQB1*0201.
Page | 14
In this type of diabetes, rate of β-cell destruction is varied. In young
individuals (mainly infants and children) the destructive process and fast
manifestation of the disease may be   with of clinical features of  ketoacidosis
and in adults it is slow. In some patients with increased fasting sugar level can
go for severe hyperglycemia and / or ketoacidosis in the presence infection and
condition like stress. This immune mediated can occur  at any age from
childhood to adolescence, though it can occur even in old age .They association
with other autoimmune disorders such as- Grave’s disease, pernicious anemia
hashimoto’s thyroiditis, vitiligo addison’s disease, autoimmune hepatitis, celiac
sprue, myasthenia gravis
Type 1B Idiopathic Diabetes
There is no evidence any etological factors or auto immunity But
most people suffered from insulinopenia and are prone to ketoacidosis. Mostly
common in African or Asian origin ,with type 1 diabetes mellitus. They suffer
from episodic ketoacidosis and show evidence of insulin deficiency of varying
degree.
Type 2 Diabetes Mellitus
Approximately more than 95% of people with diabetes, belong to
this group who usually have relative (rather than absolute) insulin deficiency
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and insulin resistance. There may be many different causes to form this
diabetes. However specific etiologies are not recognized. Most of the patients
with type-2 diabetes mellitus are obese, and obesity itself creates some degree
of insulin resistance.
Figure 3 : Factors involved in pathogenesis of Type 2 Diabetes Mellitus.
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Figure 4 : Interrelationship of Diabetes and its complications
Ketoacidosis rarely occurs spontaneously. Since hyperglycemia
develops gradually in this form of diabetes it often goes undiagnosed for many
years. Such patients are at increased risk of developing complications.
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OTHER SPECIFIC TYPES OF DM
It may be due to specific gnetic defects leads to impaired
secretion or action,or mitochondrial or metabolic abnormalities, and other
conditions that impair glucose tolerance. Penetrance by autosomal dominant
inheritance. MODY is a subtype characterized, impairment insulin secretion and
early onset of hyperglycemia.
Pancreatic exocrine disease where the majority of islets (>80%) are
destroyed.. Hormones that alienate the action of insulin can also cause diabetes
mellitus.IT is often associated with other endocrine disorder like Cushing’s
disease ,acromegaly etc.
GESTATIONAL DIABETES MELLITUS (GDM)
Diabetes induced by pregnancy because of exaggerated
physiological changes occurring in pregnancy or type 2DM unmasked or
discovered during pregnancy. It may present approximately in 4% of
pregnancies revert to normal glucose tolerance during her postpartum, having a
moderate risk of developing the disease later in their life.
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Figure 5: Effects of Gestational Diabetes. Figure 6: Risk factors for GDM
Women with strong family history, given birth to large baby
>4kg, having history recurrent fetal loss, persistent glycosuria, obese women or
over weight women >15% of non pregnant level weight are some of the risk
factor for gestational diabetes. Two types of test are available.
1. 100g glucose with 3 hour GTT.
2. With 75 g glucose and 2 hour GTT. More than 140mg/dl after 2hour of 75
gm glucose  considered as gestational diabetes.
Mechanism of insulin resistance:
Insulin resistance as evidenced by decrease in efficiency in insulin
action.In elderly obese individual insulin injection has decreased effectiveness.
Deficency in both  action and secretion of insulin must be present for diabetes to
manifest. Fasting insulin concentration is used for assessing  insulin resistance.
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Figure 7: Insulin Signaling and Control of Metabolism.
The musculoskeletal system, liver, fat and adipose tissues are
most susceptible to insulin resistance. Hereditary and environmental are also
involved in the development of resistance. There are many conditions
associated with insulin resistance such as, normally in aging population,
puberty, malnutrition, pregnancy and in abnormal conditions like polycystic
ovarian syndrome, endocrine disorders like Cushing syndrome, acromegaly,
obesity etc.
The Sodium-linked glucose transporters are present in the intestinal
system and the kidney are actively involved in the transportation of glucose
against a concentration gradient. The other glucose transporters are functioned
by facilitated diffusion. GLUT – 1,2,3,4,5 are the  five transmembrane proteins
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that functions in the similar manner. Of this GLUT-4 is an important glucose
transporter present in muscles and adipose tissues. The GLUT-4 is the main
insulin-responsive glucose transporter and is located primarily in muscle cells
and adipocytes. The post receptor defect in conducting the massage to the
insulin receptors is the mechanism for the development of insulin resistance.
Figure 8 : Mechanism of involving GLUT receptors in insulin action.
In the absence of insulin,  GLUT-4 is destroyed within the vesicles.
Within the onset of insulin secretion or exercise, GLUT-4 move to the plasma
membrane, combine with the vesicles and increase the rate of transport of
glucose into the cells. In the absence of insulin stimulation, GLUT-4 is
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re-internalized into the storage pools. Insulin acts by phosphorylation of its
receptor present in the plasma membrane.
RISK FACTORS FOR THE INSULIN RESISTANCE
The risk factors for the development of insulin resistance include:
1) Lack of physical exercise.
2) Food containing high fat.
3) Baby born with low birth rate.
4) Old-age.
5) Android obesity.
Epidemiology
Type1:Wide geographic variation in the prevalence and incidence is
present. Finland has the highest number. globally( 0-14years ) –approximately 5
laks and annually 76000 children are developing the disease.
Figure 9: Global distribution of Diabetes
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Type2: 285 million people are affected by this disorder. Global
increase of 6.6 % to 7.8% in last 20 years. China has got highest prevalence
around 30%.
Figure 10: Top 10 countries affected by Diabetes (Millions)
Gestational diabetes: More common in Asian and Indian. Around 70% women
with GDM having the chance developing the disease in subsequent pregnancy.
In INDIA: The prevalence increased from 12%to 19% in urban areas and 4%to
9% in rural areas in 2011. Andhra Pradesh and Maharashtra has highest number
of cases.
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Figure 11: Prevalence of Diabetes and Non-Diabetes in India.
Annual incidence of 18% developing the disease among IGT.
Prevalence of developing retinopathy is 27%, overt nepharopathy is about
2.3%,microalbuminuria is 27% peripheral neuropathy-26% and coronary heart
disease is 21% among the diabetes.
IMPAIRED GLUCOSE TOLERANCE (IGT) AND IMPAIRED FASTING
GLUCOSE (IFG)
10-50% of patients with impaired glucose tolerance develop Type 2
DM over a period of 10 years. Diagnostic criteria for impaired GTT are:
It is defined by two hour oral glucose tolerance test where the plasma glucose
is more than 40mm/dl but less than 200 mg.
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Figure 12: Impaired Glucose Tolerance
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Impaired fasting glucose is defined by a fasting plasma glucose of
110 mm/dl or greater but <126mm/dl.
Patients with IGT and IFG are also known as having ‘Prediabetes’.
and they are prone for micro/macro vascular complications and end up with
overt DM Type 2.
They are at risk atherosclerosis. They hence need further evaluation
at a later date since they are potential diabetics.
DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS
 Symptoms of diabetes such as frequent hungry, urination, thirst and
tiredness and blood glucose concentration 200mg/dl done randomly
Figure13: Common Symptoms of Diabetes Mellitus
 Plasma glucose content >126 mg/dL in the fasting state.
 Plasma glucose >200 mg/dL during OGTT or after two-hour of meal.
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 Random means without regard to time.
Table:3
Table3:Blood Test Levels for Diagnosis of Diabetes and Prediabetes
 Fasting means no intake for not less than 8 hrs since the last meal.
 Diabetes can be diagnosed in three possible, the  use of the
hemoglobin A1C (HbA1C is not recommended.
SCREENING
Diabetes mostly got unnoticed and diagnosed after the complications had
occured. About 1/3th of people with diabetes are still not diagnosed. However,
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early diagnosis through screening of asymptomatic individuals demonstrating
benefits. But wide spread screening test for T-2 diabetes mellitus using FPG is
justified in individuals at high risk.
Risk factors for Type 2 Diabetes Mellitus
 If a parent or sibling  of the family is suffering from increased blood
sugar.
 The chance of getting diabetes increases with age after 45
 The chance of getting the disease is greater in Hispanics, African-
Americans, Native Americans, and Asians. It develops with the  Race or
ethnic back ground.
 Metabolic syndrome.
 Patient with high lipid profile.
Figure 14: Risk factors for Diabetes Mellitus
 Being overweight as defined by body mass index
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 Higher risk of type 2 diabetes for the individual having (BMI) greater
than 25.
 Previously identified IFG or IGT
 High blood pressure increases the risk of diabetes development.
 Mother of large birth weight baby.
 Past history of vascular disease.
Recommendations
Diagnosis and evaluation can be carried out in a primary health
care system. People with Body Mass Index more than or equal to 25 kg/m2,
must be monitored for every three years beginning at age of 40-45, and if the
risk factors are present, testing should be carried out at an early stage.
First the Fasting Blood Sugar is the recommended screening if it is
abnormal then Oral Glucose Tolerance test is recommended.
.
An Fasting Blood Sugar more than 126 mg/dl is an indication for re-testing.
If FPG level is less than 126 mg/dl then there is a high suspicion for diabetes
and OGTT should be performed. A 2hr post load value of more than
200mg/dl is a positive test for diabetes.
The HbA1C remains a valuable tool for monitoring glycemic control for
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3-4 months.
STANDARDS OF MEDICAL CARE IN DIABETES
 Medical history of the patient.
 Initial recognition and evaluation.
 Symptoms, outcome of the lab tests, and special examination for the
diagnosis.
 Previous HbA1C account.
 Nutritional status, eating habits, growth and development records in the
children and adolescents stage.
 Information from previous health records. Current treatment  plan of
diabetes, including medications, intake of food items and results of
glucose monitoring and its use by the patients
 Daily lifestyle habits.
 Watching for complications such as ketoacidosis and hypoglycemia.
 Past and present status of  infections especially skin, foot, genitourinary
infections and dental.
 History of signs and symptoms and treatment of chronic kidney, eye,
nerves, genitourinary, bladder, and gastrointestinal function.
 History of medications for chronic aliment.
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 Searching for atherosclerosis risk.
 History of endocrine disorders, obesity disorders.
 History of any psychiatric disorder.
 Family history and status of diabetes and other endocrine disorders.
 History of social and environmental factors.
 History of alcohol and drug abuse.
 History of sexual misbehavior and contraception.
Physical examination
 Maturation stage on sex during pubertal period.
 Anthropometric measurement and comparison.
 Determination of hypertension, including orthostatic
measurements and compare with age-related norms.
 Fundoscope Examination.
 Examination Oral, Cardio Vascular system, Abdomine(e.g. for
hepatomegaly).
 Detection of Thyroid disorders.
 Examination of peripheral pulses.
 Examination Hand and foot, dermatological and neurological
disorders.
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 Examination to detect secondary causes of the disease.
Laboratory evaluation
 Determination of HbA1C.
 Testing of liver function.
 Testing of urine for microalbuminuria
 Analysis of renal function in adults and if proteinuria is present in
children
 Testing of thyroid profile .
 Cardiovascular examination.
 Urine- protein, sugar,deposits.
Referrals
 Examination of Eyes,.
 Testing of reproductive age women undergone family planning.
 If MNT needed,
 Dietery management.
Recommendations Diabetes in Adults \
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Table4: Summary of recommendation for diabetes in adults.
Key concepts in setting glycemic goals:
 Goal for each and every Individual person.
 special attention to vulnerable age group., pregnant mother , elderly
person and children.
For patients with strict or frequent hypoglycemia Less intensive
goals should be indicated .
Table:4.Summary of recommendations for adults with diabetes
Glycemic control
HbA1C
Fasting blood glucose
Postprandial plasma glucose
> 7.0%
90 – 130 mg/dl
< 180 mg/dl
BP < 130/80 mmHg
Lipids
Low density lipo protein
Triglycerides
High density lipo protein
Less than 100 mg/dl (<2.6 mmol/l)
lessthan150 mg/dl (<1.7 mmol/l)
more than 40 mg/dl (> 1.1 mol/l)
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 Postprandial blood sugar.
Complications
Diabetes has both acute and long term complications.2
Acute
 Diabetic ketoacidosis
 Hyperglycemic Hyperosmolar state
 Hypoglycemia
Figure 15: Complications of Diabetes Mellitus
Long term
 Retinopathy
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 Neuropathy
 Nephropathy
 Ischemic heart disease
 Cerebrovascular disease
 Peripheral vascular disease
 Hypertension.
 Others
Infections
 UTI
 Tuberculosis
 Candidiasis – oral / volvovaginal
 Mucor mycosis
 Necrotising fasciitis
 Periodontitis
 Duputrens contracture
 Pseudogout
DIABETIC RETINOPATHY :
It is sight threatening chronic micro vasculature complication mostly all
patient of diabetes.
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Figure 16: Showing the difference between Normal retina and Retinopathy.
It lead to retinal non perfusion, increased vascular permeability,
intra ocular proliferation blood vessels(macular edema)and uncontrolled neo
vacularisation (proliferative retinopathy)leads to severe visual loss.
CLASSIFICATION :
Figure 17 : Flow Chart showing stages of Diabetic Retinopathy
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1.No apparent retinopathy.
2. Mild NPDR-micro aneurysms only
:
Figure 18: Non-proliferative retinopathy
3.Moderate NPDR-more than micro aneurysms but less than severe NPDR
Figure 19: Moderate Non-proliferative retinopathy
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4.Severe NPDR->20 intra retinal hemorrhages in each quadrant,venous
beading,prominent micro vascular abnormalities and no PDR.
5.PDR-One or more retinal neovascularization,vitreous hemorrhages,pre retinal
haemorrhages.
Figure 20: Proliferative Diabetic Retinopathy
Macular edema: classified into two types
1. Not apparent-no retinal thickening or hard exudates in the posterior pole,
2. Apparent- presence of hard exudates,(mild-retinal thickening but distinct
from Centre of macula, mod-thickness grows towards the centre, severe-
involving whole macula.
Other ocular complication: Mono neuropathies involving 3,4,6 nerves, neo
vascular glaucoma, open angle glaucoma, change in the refractive error, cataract
bulbar conjunctivitis etc.
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Figure 21: Macular edema
Diabetic retinopathy starts with mild NPDR and progress
through moderate and severe NPDR to proliferative diabetic retinopathy.
Macular edema can develop at all stages. NPDR generally develops later part of
the first decade or early 2nd decade of type – 2 diabetes mellitus. PDR usually
develops within 5 years of NPDR. Pregnancy, hypertension, poor glycemic
control, and cataract surgery may accelerate these changes. For every
percentage reduction of HbA1C (eg. From 8 to 7%), there was a 35% reduction
in risk of retinopathy,19and tight BP control (to < 150/85 mmHg) results in 34%
reduction in progression of retinopathy.
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Diabetic Nephropathy
Figure 22: Diabetic Nephropathy
World wide, diabetes is one of the most responsible cause of (ESRD).
About 25% of patients with diabetes show evidence of nephropathy, but in type
2 diabetes a smaller proportion of these patient may advanced into end stage
renal disease. Due to higher prevalence of type 2 diabetes mellitus, they may
constitute over half of patients with nephropathy needing to do dialysis.1 The
diabetic nephropathy progresses from appearance of low but abnormal levels (≥
30mg to 299 mg/day or 20µg/min) of albumin in urine (microalbuminuria stage)
to stage of macroalbuminuria / clinical albuminuria (≥300mg/dl or ≥200µg/min)
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to ESRD. Microalbuminuria to macroalbuminuria normally takes 10-15 years.
ESRD develops within 10 years in 50% of type 1 diabetic individual with
nephropathy and in 20 years by 75%. But in type 2, even after 20 years of overt
nephropathy only 20% progress to ESRD.
Screening for Microalbuminuria
A test for the presence of urinary microalbumin should be done
for every six month in patients with type 2 diabetes mellitus and after 5 years of
disease. In type 1 diabetes mellitus, this repeated annually. It can be performed
by three methods.
 Spot estimation protein to creatinine ratio in urine 24 hr Urine
collection and estimating of albumin excretion.
 Timed (e.g. 4 hr or overnight) collection.24 hr collection of
urine is most reliable.
Table:5Diagnostic values of Albuminuria in Diabetes
condition spot
collection
(mg/dl)
24 hrs
collection(mg/24hrs)
Timed
collection
(µg/minute)
Normal <30 <30 <20
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Table 5: Abnormalities of urine secretion
In addition this, earliest manifestation of nephropathy, marker of greatly
increased cardiovascular morbidity and mortality for patients with either form
ofdiabetes.
Diabetic Neuropathy
Diabetic neuropathy occurs in fifty percent patint with long standing type
1 or type 2 diabetes mellitus . neuropathy correlates with glycemic status and
the duration of disease.
Figure 23: Diabetic Neuropathy
Micro
albuminuria
30-299 30-299 20-199
Clinical
albuminuria
> 300 > 300 > 200
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Classification
It envolves both limbs lower more than upper symptoms pain paresthesias, and
dysesthesias. Small fibre neuropathy is less common and alpha and C fibre are
more involved causing burning or stabbing in nature, more severe at night.
Large fibre neuropathy leads to electrical tingling like sensation. The patient
may have sense of imbalance with gait instability.
Symmetric
 Distal, primarily sensory polyneuropathy.
 Autonomic neuropathy
 Chronic proximal motor neuropathy
Asymmetric
 Acute or subacute proximal motor neuropathy.
 Cranial mononeuropathy
 Truncal neuropathy
 Entrapment neuropathies
Also classified as follows (Watkin’s and Edmond’s classification)21
1. Progressive Neuropathies
 Chronic sensory motor neuropathy
 Autonomic neuropathy
2. Reversible Neuropathies
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 Mononeuropathies
 Proximal motor neuropathy (Amyotrophy)
 Cranial nerve palsies (III,IV,VI)
 Truncal radiculopathies
 Acute painful neuropathies
3.Pressure Palsies
 Carpal tunnel syndrome.
Distal symmetric polyneuropathy : Glove and stocking like sensation in
both lower limbs and involves the hands in severe cases. All sensory
functions may be affected. Ankle reflex may be reduced or absent and
wasting of small and in severe cases large muscle may occur. Most
common form of diabetic neuropathy and most frequently represents as
distal sensory loss. Hyperesthesia, paresthesia and dysesthesia may also
be occur.  Painful neuropathies may develop in these patients. Acute
(lasting < 12 months) as well as chronic form of painful diabetic
neuropathies have been described below.
Individuals with long standing type 1 or type 2 diabetes mellitus may
develop autonomic neuropathy. It involves all system including
cardiovascular, gastrointestinal, genitourinary and metabolic systems.
Resting tachycardia, gastroparesis orthostatic hypotension, hyperhidrosis
of upper extremities, bladder emptying abnormalities, and anhidrosis of
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lower extremities are features of diabetic autonomic neuropathy.
CARDIOVASCULAR DISEASE IN DIABETES
Incidence cardiovascular disease is increased in individuals with type 1 or
type 2 diabetes mellitus. A Study conducted by the Framingham Heart revealed
that a marked increase in peripheral arterial disease, coronary artery disease,
myocardial infarction, congestive heart failure and sudden death (risk increases
from one to five fold) in diabetes mellitus.22 The American Heart Association
recently designated type 2 diabetes mellitus as a coronary risk equivalent i.e.
they have a similar 10 year risk of MI, as those who have had a prior MI.1
Because of extremely high prevalence of underlying cardiovascular disease in
patients with type 2 diabetes mellitus, evidence of atherosclerotic vascular
disease should be sought in a diabetic who has symptoms suggestive of cardiac
ischemia, peripheral or carotid artery disease, a resting ECG indicative of prior
MI, plans to initiate an exercise program, proteinuria or two other cardiac risk
factors. (ADA recommendations).1
In addition to coronary artery disease, cerebrovascular disease is
increased in individuals with diabetes mellitus (three fold increase in stroke).
Proof that improved glycemic control reduces cardiovascular complications in
diabetes mellitus is lacking.16
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Magnesium
Magnesium is the fourth most abundant cation in the body and second
most ion in intracellular tissue  materials. Magnesium content in an adult
human body is 21-28gms (approximately 2000mEq). About 60% of total body
magnesium is concentrated in bone and the remainder is in soft tissues. The soft
tissue intracellular compartments comprise about 38% of which higher
concentrations are found in liver and skeletal muscle. (15-20 mEq/Kg). Less
than 2% is present in extra cellular fluid (ECF) compartment.23 Magnesium
concentration in serum ranges from 1.7 to 2.4 mg/dL. (0.7 to1.0 mol/L). The
plasma concentration in healthy adults remain remarkably constant.7 It is
pertinent to point out that limits of the normal range deviate by less than 15
percent from the mean, indicate that the serum concentration is maintained by
sensitive control mechanisms, which are poorly understood at present.
Daily intake average  magnesium is of the order of 25 mEq (140-360
mg/day). Dietary magnesium is absorbed less than 40% throughout the small
intestine particularly in the ileum. Elimination is predominantly renal and
averages 100mg/day. The upper limit of the normal range for urinary excretion
is threshold. Thus, magnesium excretion increases dramatically when serum
levels rise above 2.4 mg/dl, conversely, the kidney maintains a strong capacity
to reabsorb magnesium when the condition of magnesium depletion prevails,
The main site for re-absorption is the thick ascending renal re-absorption, such
Page | 46
as hypercalcemia, volume expansion and diuretic administration (eg. osmotic,
thiazide or loop diuretics).24oop of Henle. Impairment of renal re-absorption
may be caused by several factors.
BIOCHEMICAL IMPORTANCE OF MAGNESIUM
Magnesium is an important  activator in a host of enzyme systems that
are critical to cellular metabolism including hydrolyze and transfer phosphate
groups, especially those involved in the reactions involving adenosine
triphosphate (ATP). As ATP is necessary for glucose utilization, protein, fat,
nucleic acid and co-enzyme synthesis, muscle contraction and other reactions
by inference the activating effect of magnesium extends to all these functions.
In addition to this, for oxidative phosphorylation in the mitochondria
magnesium is required as a cofactor.5
Magnesium contributes significantly to macromolecular structure. The
highly ordered  organization of DNA, RNA and ribosome is stabilised by
presence of this metal.26,27 In protein synthesis also magnesium is involved by
contributing to the binding of messenger RNA to the 70s ribosome.28
Interrelations of major biologic cations
 Magnesium generally found in high concentrations within the cell, where
as the content calcium in the intracellular is low. The ratios are inverted
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in extracellular fluid.29
 Variations in dietary calcium do not affect the absorption of magnesium.
 Magnesium reabsorption in renal tubules is inhibited by hypercalcemia.
 The intracellular phosphate concentration is usually parallel to
magnesium concentration
Regulation of Serum Magnesium
Renal regulation
Regulation of concentration of serum magnesium is mainly achieved by
control of renal magnesium reabsorption. About 20% of the filtered
magnesium is reabsorbed in the proximal tubule, where as 60% is generated in
the cTAL (thick ascending loop) and another 5-10% in DCT (Distal tubule).
Magnesium reabsorption in cTAL is increased by parathyroid hormone and is
inhibited by hypercalcemia and hypermagnesemia.7
Intestinal absorption
Around 30-40% of dietary magnesium (normally ranges from 140 – 360
mg/day) is absorbed, mainly in the ileum and jejunum. The efficiency of
Intestinal magnesium absorption is stimulated by 1,25 (OH)2 Vitamin D and it
can reach 70% during magnesium deprivation.7,30
Hormonal factors
33
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Increasing serum magnesium,30
 Parathyroid hormone
 Glucagon
 1, 25(OH) 2 Calcitriol.
Decreasing serum magnesium,
 Aldosterone
 Vasopressin (ADH)
 Thyroxine
 Calcitonin
Dietary Reference Intakes for Magnesium
Recommendations for magnesium are provided in the dietary reference
intakes (DRI’s) developed by the Food and Drug Administration
(FDA).31Recommended Dietary Allowances (RDA) for magnesium are as per
the table.
Table 6 :Recommended Dietary Allowances Magnesium values in mg/day).
AGE
(years)
MALE FEMALE PREGNANT LOCATION
1-3 80 80 N.A N.A
4-8 130 130 N.A N.A
9-13 240 240 N.A N.A
14-18 410 360 400 360
19-30 400 310 350 310
31+ 420 320 360 320
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Selected Food Sources of Magnesium content (in mg/100m)
Nuts like cashew contain 260,almonds contain315, peanuts175 mg/100mg
Split Beans contain 50 mg, soya bean-86mg/100mg of legumes
Fruits like banana contain 30mg/100mg, dates contains35mg/100mg,apple
contains50mg/100mg of magnesium.
Milk product like butter contains20mg/100mg,Yogurt contains 12 mg/100mg,
Milk contains24mg/100mg of magnesium. Cereals like wheat contains
10mg/100mg,Rice contains 40mg/100mg,meat and fish contains 20-
22mg/100mg Greens like spinach contains highest concentration of serum
magnesium. 22
Hypermagnesemia
Normal kidneys are capable of excreting large amount of magnesium
upto 250mmol/day.Hence hyper magnesemia is a rare occurance.
Causes of hypermagnesemia
1. Due to decrease excretion of magnesium as occur in
 Chronic Renal failure and
 Familial hypocalciuric hypercalcemia
2.Increase  intake of magnesium like
 Parenteral magnesium administration (eg.magnesium sulfate in
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PIH)
 Laxatives
 Antacid preparations
3. Rapid magnesium mobilisation from soft tissues like
 sepsis
 Severe burns
 Extensive burns
 Shock,
 Post-cardiac arrest
 trauma
 Other disorders like
 Adrenal insufficiency
 Hypothyroidism
 Hypothermia
Clinical features
The most prominent clinical manifestation of hypermagnesemia depends
upon serum level of magnesium 1. neuromuscular blockade and vasodilation,
which appear at serum magnesium concentrations at > 4.8 mg/dL (>2mmol/L).
Hypotension, refractory to vasopressors and expansion of volume, may be an
early signs. Lethargy and weakness may progress to respiratory failure,
paralysis and coma with hypoactive tendon reflexes (at serum magnesium is > 4
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mol/L levels). Gastrointestinal hypomotility or ileus may occur. Prolongation of
PR, QRS intervals, heart blocks and approaching the serum magnesium levels
at 10 mmol/L, asystole.
Treatment
Generally involves identifying and avoiding the source of magnesium.Vigorous
intravenous hydration and hemodialysis may be necessary. Calcium, given
intravenously in doses of 100-200 mg over 1 to 2 hrs provides temporary
improvement.
Hypomagnesemia
Hypomagnesemia signifies substantial decrease of body magnesium stores (0.5
to 1 mmol/Kg). Hypomagnesemia has varied etiology. Dietary magnesium
deficiency is unlikely except in the setting of alcoholism
.24
Causes of Hypomagensemia24
I. Impaired intestinal absorption
A. Primary infantile hypomagnesemia
B. Malabsorption syndromes
C. Vitamin D deficiency.
II. Increased intestinal losses
1. Protracted vomiting / diarrhea
2. Intestinal drainage, fistulae
III. Impaired renal tubular reabsorption
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A. Genetic magnesium wasting syndromes.
1. Gitelman syndrome
2. Bartter syndrome
3. Na-K ATPase g-subunit mutations
B. Acquired renal disease
1. Tubulointerstitial disease
2. Post obstruction /ATN (diuretic phase)
3. Renal transplantation.
C. DRUGS
1. Ethanol
2. Diuretics (loop, thiazide and osmotic)
3. Cisplatin, cyclosporine
4. Aminoglycosides, Amphotericin B
IV. Metabolic causes
1. Hyperaldosteronism
2. SIADH
3. Diabetes mellitus
4. Metabolic acidosis
5. Hypercalcemia
6. Hyperthy roidism
V. OTHERS
1. Pancreatitis
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2. Excessive sweating
3. Osteoblastic metastases
Several genetic magnesium wasting syndromes are explained, but are
extremely rare. Protracted nasogastric suction, parenteral fluids, infected
diarrhea, steatorrhoea, inflammatory and bowel disease may cause
hypomagnesemia.33 Magnesium deficiency common in patients  especially
those who receives furosemide diuretic34.
Frequency
Hypomagnesemia is a common entity occurs in up to 12% of hospitalized
patients35. Incidence are known as high as 60% in patients in intensive care
settings in which nutrition, hypoalbuminemia diuretics and aminoglycosides
may play important roles.36
Risk of incidence is as follows:37
1. In general population2%.
2. In hospitalized patients10 – 20%.
3. In ICU patients. 50 – 60%
4. In Alcoholics30 – 80%.
5. In diabetic outpatients25%.
Sex: Incidence is equal in males and females.
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Clinical features
.2,38
History
 Presence of hypomagensemia can be found by obtaining history of
potential causes (see table).
 Complaints related to hypomagensemia are nonspecific.
 Patients may have weakness, muscle cramping or rapid heartbeats.
 Altered mental status such as irritability, apathy, psychosis, delirium etc
may be present in severe cases. Less severe cases may result in vertigo,
ataxia, depression and seizure activity.
Physical signs
Symptoms and signs appear only when serum magnesium concentrations
are <1.2 mg/dL (0.5 mmol/L). The primary clinical observations are
neuromuscular irritability, cardiac arrhythmias  and CNS hyperexcitability
.39
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Signs
 Deep tendon hyperactive reflexes.
 Cramps of muscles.
 Trousseau and Chvostek
 Esophageal dysmotility causes Dysphagia
 Disorientation or Irritability
 Ataxia, seizures or nystagmus (at levels <0.8 mg/dl) Paroxysmal
arterial and
 ventricular dysrhythmias.
ECG
Depletion of magnesium can induce changes in the electrocardiogram.
Findings in hypomagnesemia are nonspecific. Modest magnesium depletion
(1.2 to 1.7 mg/dl) leads to widening of QRS complex with peaking T-waves,
while more severe magnesium deplection (<1.2 mg/dl) is associated with
protracted PR interval, progressive widening of QRS complex, flattening /
inversion of T-waves and U waves.40 Cardiac arrhythmias may occur including
sinus tachycardia, other ventricular arrhythmias and supraventricular
tachycardia.
Lab Studies
The serum magnesium level cannot a reliable determinant of total
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magnesium depletion in the body because only a small fraction of magnesium in
the body is extra cellular. However, if serum level is low indicates a clear
deficiency of magnesium. 41
Serum magnesium levels may be estimated by several methods.
 Neutron activation analysis
 Atomic absorption spectrometry
 Ion selective electrodes (ISE)
 Equilibrium dialysis
 Calmagite dye method.
Calcium, potassium and phosphorous levels must be assessed.
 BUN and creatinine levels.
 Blood glucose level.
Treatment
The mechanism of magnesium repletion varies with severity of the clinical
manifestations. As an example, the hypocalemic-hypomagnesemic patient with
tetany or the patient with hypomagnesemic ventricular arrhythmias should
receive 50 mEq of IV magnesium slowly over a period from 8 to 24 hours. To
maintain plasma magnesium concentration above 1.0 mg/dl.42, this dose can be
repeated as necessary
In less critical patients, oral replacement should be given preferably with
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a sustained release preparation. There are several such preparations available
such as Slow Mag (magnesium chloride) and MagTab-SR (Magensium lactate).
These preparations can give 60-84mg (2.5 to 3.5 mmol) per tablet. For severe
magnesium depletion (<1.2mg/dL) six to eight tablets should be taken daily in
divided doses. For milder disease two to four tablets are enough to control. If
necessary, addition of potassium sparing diuretic in those who cannot
discontinue diuretic therapy, discontinuation of diuretic therapy,, treatment of
chronic diarrhea etc.2
HYPOMAGNESEMIA AND DISEASE CORRELATES
Magnesium and cardiovascular diseases
The close associations of magnesium metabolism, diabetes and high
blood pressure may likely to cardiovascular disease.
Arrhythmia
Magnesium depletion can also induce change in the electrocardiogram.
But, there are conflicting data as to whether hypomagnesaemia is associated
with arrhythmia in otherwise healthy subjects. It is learnt that a study  over
3000 patients from the Framingham Heart suggests that the manner in which
arrhythmia is defined is an important determinant.40 No association with
hypomagnesemia was noted for more than 10 ventricular premature complexes
(VPC) per hour or for repetitive VPC. Nevertheless, an increased risk of
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complex or frequent (>30/hr) VPC with reduction in plasma magnesium
concentration of 0.2 mg/dL (0.08 mmol/L) or more. The clinical disturbance of
greatest potential importance is however, the association of mild
hypomagnesemia with ventricular arrhythmias in patients with cardiac disease.
A number of uncontrolled studies suggest that hypomagnesaemia may be an
important risk factor for arrhythmias in the setting of an acute ischemic event,
torsade de pointes and congestive heart failure, after cardiopulmonary bypass or
in acutely ill patient in the intensive care unit.43,44
Arrhythmias could be due to hypomagnesemia itself, concurrent
hypokalemia, or both. Magnesium regulates and maintain several cardiac ion
channels, including the calcium channel and outward potassium currents.45
Lowering of cytosolic magnesium concentration will markedly increase these
outward currents, shortening the action potential and increasing susceptibility to
arrhythmias.
Torsade de Pointes
Magnesium sulfate can be added for the management of torsade de
pointes, or refractory ventricular fibrillation.46 as recommended by the
American Heart Association, 1992 and gives guidelines for Cardio pulmonary
resuscitation and emergency cardiac care. Torsade De pointes is a unique
ventricular tachycardia most commonly precipitated by drugs that prolong the
QT interval (e.g. Quinidine), electrolyte imbalance (hypokalemia and
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hypomagnesemia), or a slow heart rate. Treatment has to be done with an aim of
accelerating the heart rate and/or shortening the QT interval. Treatment of
intravenous magnesium is now considered even when hypomagnesemia is not
present.42
Hypertension
Magnesium has playing important role in reducing blood pressure.47 It is
a antagonist of calcium and important  activator of  sodium potassium ATPase
When the serum magnesium level decreases which in turn lead to raising
intracellular concentrations of calcium and potassium, which in turn causes
increase in peripheral vascular resistance and vasoconstriction.
Magnesium may also have a direct impact on vascular smooth muscle.48
In one study of clinical trial 73 patient selected by random methods, subjects
not taking oral diuretics or other pharmacological drugs affecting the
metabolism of magnesium, Petersen et al found  the relation between serum
magnesium level and blood pressure was an inverse correlation.49
Additingly, research showed that patients with hypertension having
hypomagnesemia frequently needs more antihypertensive drugs than
hypertensive patients with normal magnesium levels. In another study using
placebo controlled trial, showed magnesium supplementation in patients  taking
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long term oral diuretic treatment for systemic hypertension, achieved noticeable
decrease in blood pressure, by average of  12mmhg in systolic and diastolic
pressure of 5mmhg.
The Joint National Committee (JNC) for  recommendation for prevention,
detection, evaluation treatment of high blood pressure stress the importance of
maintaining an adequate level of magnesium intake as a positive changes  in
life style modification for preventing and managing high blood pressure.
Magnesium and ischemic heart disease
Some observational surveys showed in their studies, higher blood levels
of magnesium associated with lower risk in the incidence of coronary artery
disease. Two studies, prospective epidemiological studies involving large
people, have examined the relationship between the serum magnesium level and
development of coronary heart disease subsequently. They suggested that a low
level of serum magnesium is a important risk factor for the development of
coronary artery disease.52,53 One study, involving15,792 people, in observational
study, examined and followed  the subjects in the age group of 45 to 64 years,
for a seven year period as part of the Atherosclerosis Risk In Communities
Study (ARIC). They found that both men and women who developed CHD had
serum magnesium concentration at a lower mean level than the disease free
controls. The relative risk of CHD across the quartiles of serum magnesium
concentration decreased from lowest quartile to higher quartiles. But
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pathophysiologic mechanism causing low serum magnesium that might
predispose to  coronary heart disease is not known.
Many smaller studies also suggested that supplementation of magnesium  may
lead to improvement in the exercise tolerance, may have an additional
protective antithrombotic effect with  drug like aspirin and may causing
improvement in clinical outcomes in individuals  suffering from coronary artery
disease
Acute Myocardial Infarction
Acute MI is frequently associated with marked reduction in serum magnesium
concentraion.55 Mild decrease in serum magnesium associated with acute
myocardial infarction appears to give rise to a 2 to 3 fold increase in the
incidence of ventricular arrhythmias in the first twenty four hours period, in
related to those with presence of normal serum magnesium levels.44 A study
done by Uncontrolled trial method suggested that the administration of parental
magnesium at this time can decrease the frequency of potentially fatal outcome
of ventricular arrhythmias.
A relationship has also been found between ventricular arrhythmias and levels
the plasma magnesium and occurring in the second or third week after
myocardial infarction. In one study stats that in patients with no abnormal
rhythm, the average level of plasma magnesium concentration was 1.83
mg/dl,and in patien with multifocal ventricular premature complexes the level
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of serum magnesium was1.68 mg and 1.55 mg/dl in patient  suffering from un
sustained ventricular tachycardia. Complex arrhythmias are seen in thirteen
patient and hypomagnesemia was found out corrected with intravenous
magnesium; and normal sinus rhythm was restored.
Magnesium and congestive heart failure:
In patients suffering from congestive heart failure an
increased incidence of hypomagnesaemia has been found repeatedly. and is
mainly due in part to therapy diuretic drugs. A role for magnesium depletion in
sudden death has been suggested but pathophysiological mechanism  that causes
death is not proven.  No correlation was found between hypomagnesemia and
class III or IV heart failure in a prospective study attended by more than 1000
patients done at the beginning of the study and survival at a median follow up of
6 months.
 Osteoporosis- In postmenopausal women magnesium deficiency may play an
additional risk factor for development of osteoporosis. It may be noted that
magnesium deficiency is altered with calcium metabolism and the hormones
that regulate the calcium metabolism. Several human studies have suggested
that bone mineral density may improve with. magnesium supplementation.
 Dietary surveys have proved that a increased level of magnesium intake is
associated with decreased incidence of cerebrovascular disease
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 Asthma: Magnesium plays a important role in maintenance of lung structure
and function. Magnesium acts by blocking the function of calcium, which leads
to contraction of bronchial smooth muscle
.62The decreased magnesium level
also has an effect on immune response. A diet high in magnesium is directly
related to healthy lung function and a reduced risk of airway hyper reactivity.
Increase in the incidence of bronchia; asthma associated with
hypomagnesemia.63
 Parathyroid hormone resistance: Studies have shown that the decrease in
serum magnesium level interferes with improvement in hypocalcemia in
response to parathyroid hormone and symptomatic hypocalcemia is almost
always associated with serum magnesium levels below 1.2 mg/dl (0.5 m
mol/L).64
 Magnesium depletion is also related to increased plasma LDL, cholesterol and
tirglyceride and reduced plasma HDL
.65
Magnesium and diabetes
Magnesium ion has a fundamental role in the metabolism of
carbohydrate metabolism and Diabetes mellitus has been suggested to be the
most common metabolic disorder associated with magnesium deficiency, with
the of 25 to 39% 5,6,7
The clinical implications of magnesium deficiency as it relates to diabetes
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are many. Hypomagnesemia as a consequence un-contolled of hyperglycemia
(associated  with increased urinary magnesium excretion along with glycosuria)
and a cause resistance of insulin. The relation between diabetes mellitus and
hypomagnesaemia is compelling for its wide ranging impact on hyperglycemic
control, complications, and ultimately therapy. Although poor glycemic control
is associated with magnesium deficiency, it is not simply induced by
hyperglycemia and is not corrected by improvement in metabolic control alone.
Magnesium depletion has been associated with the development of diabetic
retinopathy.10 Of greater importance is the association between decrease in
magnesium level and systemichypertension,5066 66 insulin resitance thrombotic
tendency,66,67 and the Reaven – Modan syndrome, a rare clinical entity that links
diabetes mellitus, hyperinsulinemia, 68increased thrombotic tendency
hypertension and tendency – all cardiovascular risks
.
Causes of hypomagnesemia in diabetes mellitus
Initially, the cause of hypomagnesemia in diabetes was attributed to (1) o
glycosuria due to osmotic renal losses (2) decreased in intestinal magnesium
absorption and (3) due to insulin effect there is redistribution of magnesium
from plasma to red blood cells. Recently a specific tubular magnesium defect in
diabetes has been postulated. A reduction in tubular absorption of magnesium
results in hypermagnesuria. The exact site of re-absorptive defect is not yet
defined. This is postulated to be either in the thick ascending loop of Henle or
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more distal loop of Henle.
The cause of this tubular defect in magnesium resorption also is not clear.
Insulin treatment has been shown to correct diabetic renal losses of magnesium
.The delayed insulin treatment may be less effective in correcting the renal
electrolyte losses, suggesting some irreversible component.
The role of magnesium in insulin action
Magnesium is involved in various levels in insulin secretion, binding and
activity. Magnesium is a important cofactor of many enzymes involved in
carbohydrate metabolism.
Figure 24 : Mechanism of action of Mg
In addition to these effects of magnesium, magnesium deficiency has
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been shown to associated with insulin resistance in multiple studies.
Figure 25: Relationship between Glucose and Insulin resistance
In a recent study, Attenuation of the cellular uptake of magnesium,
which is normally stimulated by insulin, was present  in patient with diabetes..
There is also evidence that magnesium deficiency itself produces
insulin resistance. Nadler et al.8 studied 16 non diabetic subjects and found that
insulin sensitivity felt after induction of magnesium deficiency.
Likewise, in elderly non-diabetic normo-glycemic subjects were shown to
have improved glucose handling, when they take regular magnesium
supplements for 4 weeks.74 There was a direct relationship between
intracellular magnesium concentration and glucose metabolism, thus
implicating magnesium deficiency in the insulin resistance of aging. In non
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diabetic obese subjects, insulin resistance was found along with low magnesium
levels, when compared with non obese subjects, again highlighting the
association between hypomagnesemia and insulin resistance.75
An intriguing theory, suggested by Tonyai, et al.76 is that membrane
viscosity may altered with a low erythrocyte magnesium content , and this may
reduce the interaction of insulin with its receptor on the membrane. Paolisso et
With the long-term of magnesium administration can reduce membrane micro
viscosity
.
Role of magnesium deficiency in diabetic end organ damage
Magnesium deficiency has been frequently found to be associated with
diabetic microvascular disease. Decrease level of has been demonstrated in
patients with diabetic retinopathy, with lower serum magnesium levels
associated with a greater risk of severe diabetic retinopathy.10 Magnesium
depletion is also found to play a role in patient with diabetic polyneuropathy.
Corsonello, et all have reported an association between diabetic nephropathy
and magnesium depletion.
Microalbuminuria and clinical proteinuria, as well as poor glycometabolic
control and hypertriglyceridemia, are associated to relevant alterations in serum
ionized magnesium.
Magnesium depletion has been associated with multiple cardiovascular
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complications: arrhythmias, vasospasm, hypertension and platelet activity
.43,50
Three exciting theories link diabetes and its vascular complications to
hypomagnesemia: the inositol transport theory, oxidative stress and the ionic
hypothesis of metabolic disease
Grafton, et al4 have focused on the inositol transport theory. It has been
one of the favored explanations for the origin of diabetic complications.
Figure 26: Role of Mg in Type 2 DM
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The association between magnesium deficiency, essential hypertension,
insulin resistance, hyperinsulinemia68, and ischemic heart disease (Reaven-
Modan Syndrome) may be proved by the ionic hypothesis of cardiovascular and
metabolic disease, proposed by Resnick.
:
Table 7: Causes of Mg deficiency
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Diabetes is a state of increased free radical activity.
Figure 27: showing Mg rich food
Magnesium deficiency has been shown to reduce functions of natural
antioxidants like glutathione, ascorbic acid and Vitamin E.
EVIDENCE FOR EFFICACY OF MAGNESIUM SUPPLEMENTATION
IN DIABETES MELLITUS
There is more number of evidence that repletion of magnesium can
ameliorate the insulin resistance, platelet reactivity and other cardiovascular risk
factors associated with hypomagnesemia and diabetes mellitus.78
In a study of 16 diabetics and 30 healthy controls, oral replacement with
magnesium hydroxide at a dose of 250mg twice daily resulted in decreased
insulin requirements in the diabetic patients. In elderly type 2
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diabetics,Paolisso,74 et al demonstrated that oral magnesium supplementation
given for four weeks resulted in lower the fasting plasma glucose levels,
increased plasma magnesium levels and though a slight, but statistically
significant increase in beta-cell response to glucose and arginine. In type 2
diabetics, oral supplementation of magnesium has been shown to decrease
platelet reactivity, lower systolic blood pressure by 7 mm Hg and to result in a
beneficial effect on lipid profile
.
CLINICAL APPROACH TO MAGENSIUM SUPPLEMENTATION IN
DIABETES MELLITUS
The consensual conference on magnesium supplementation sponsored by
the American Diabetes Association warrants a more interventionist approach to
hypomagnesemia
.
There are no accurate tests clinically available to determine intracellular
magnesium depletion routinely in diabetics. With 99% of the body stores of
magnesium being intracellular, low serum magnesium level is an insensitive,
yet precise measure of total body stores. Certainly, patients at risk for
hypomagnesaemia should have serum magnesium measured. This includes
diabetics with clinical states known to be associated with hypomagnesaemia
such as, ketoacidosis, alcohol abuse, long term parenteral nutrition, chronic
diarrhea or use of diuretics, acute myocardial infarction, ketoacidosis / digoxin.
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Additionally, patients at high risk of cardiac events such as arrhythmia and
vasospasm, should be considered for magnesium replacement.
Whether the broader range of magnesium related abnormalities, such as
hypertension, hyperlipidemia and insulin resistance of diabetes itself, should be
treated with repletion requires a randomized clinical trial to determine.
However, each patients individual risks for hypomagnesemia, cardiovascular
risks and risks related to therapy need to be assessed. Overt serum
hypomagnesaemia should always be corrected. If hypomagnesemia is clinically
suspected, but cannot be documented by serum levels, a further test with
erythrocyte or platelet magnesium concentration is necessary. Renal
insufficiency, especially with creatinine clearance of less than 30 ml/min is the
only factor that precludes dietary supplements. Magnesium chloride is the
preparation of choice (Slow Mg). Doses of 100 to 600mg/day may be necessary
to correct repletion. Diarrhea is the dose limiting side effect
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METHODOLOGY
Source of data
Patients with type 2 diabetes attending in Chengalpattu Medical college&
Hospital,  Chengalpattu, Kanchipuram district, , over a period of one year
between 1st September 2013 to 30th to September 2104.
Sample size
The sample size was 100 patients.
Study population
One hundred randomly selected patients with type – 2 diabetes mellitus
on oral hypoglycemic agents (OHAS) and/or insulin treatment attending as in or
out patients in  Chengalpattu medical college& Hospital   constituted the study
population.
Out of these, 67 were men and 33 were women. The mean age of
subjects was 58.3 years with a range of (40-78) years. The median (range)
duration of diabetes was 5.5years (01-22 years). Of these patients, 69 patients
were receiving OHAs alone, 5 patients insulin alone and 20 were receiving both
insulin and OHAs. 32 of these subjects had hypertension and 16 had coronary
heart disease. Patients with renal failure, acute myocardial infarction, patients
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on diuretics, alcoholics or with mal-absorption were excluded. None were
taking magnesium supplements or magnesium containing antacids. Consent was
obtained.
Inclusion criteria
All patients suffering from type 2 diabetes mellitus admitted in in
Chengalpattu medical college& Hospital  .
Exclusion criteria
1. H/O. Patients suffering from chronic renal failure.
2. H/O  Acute myocardial infarction for last 6 months.
3. Patients  is on diuretic drug therapy
4. Patients with h/o of alcohol abuse.
5. Patients receiving magnesium supplements or magnesium containing
antacids.
6. Mal-absorption or chronic diarrhea
Data collection
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The 100 diabetics (with median diabetic history of 5.5 years) were
included in the study. Detailed history – including duration of diabetic illness,
mode of treatment ,symptoms suggestive of diabetic retinopathy nephropathy ,
associated diseases such as  systemic hypertension and ischemic heart disease
were obtained, as per the proforma.
Followed by physical and neurological examination, and ECG.
Retinopathy was assessed by direct opthalmoscopy. Blood specimen were
collected for testing of fasting blood glucose and plasma magnesium.  sugar was
measured two hours after a standard meal. Blood urea, serum creatinine and 24
hour urinary albumin were estimated. Serum magnesium was estimated by
Calmagite dye method. HbA1C was measured.
Calmagite dye method for quantitative estimation of serum magnesium
Test principle
Under alkaline conditions, magnesium ions react with calmagite dye to
produce a red complex which is measured spectrophotometrically at 530 nm.
Intensity of the colour produced is directly proportional to magnesium
concentration in the serum. To eliminate the interference of calcium during
estimation, EGTA is included in the reagent.
Test procedure
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These test tubes are incubated at room temperature (22-28ºC). The absorbance
of Test (AT), Standard (AS) and Blank (AB) are read at 530nm
spectrophotometer. Magnesium concentration is calculated by the following
formula.
In test
tubes
Blank Standard Test
Calmagite
reagent
1.0ml 1.0ml 1.0ml
Patient sample 10ml 10ml
Standard
sample
Distilled water 10.0ml
Magnesium concentration (mEq/L) = (AT-AB / AS-AB) x 2
Serum magnesium concentration is expressed in mg/dl by
linearity of 1 mEq/L = 1.2 mg/dl.
Subsequently patients were divided into three groups based on their
following values: Normal, 1.7 to 2.4 mg/dl, low <1.7mg/dl, high >2.4 mg/dl.
Patients were also categorized on the basis of duration of diabetes, presence of
ischemic heart disease or systemic  hypertension, mode of treatment,
presence/absence of retinopathy, neuropathy and nephropathy, and glycemic
control (FBS and HbA1C). Patients with diabetic retinopathy were further
classified as those with non-proliferative diabetic retinopathy (NDPR) and those
with proliferative diabetic retinopathy (PDR). Diabetic nephropathy was graded
depending on 24 hour urinary excretion of albumin as follows: No nephropathy,
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< 30mg/24hour, microalbuminuria 30 – 299mg/24hour and macroalbuminuria
(clinical proteinuria) >= 300 mg/24hour.
Statistical method
Statistical method analysis was done using Chi-square test and Fisher’s
exact test to compare proportions. Statistical results were considered significant
at P value < 0.05
RESULT
100 persons affected  by type – 2 diabetes (68 male, 32 female, mean age
58.5 years) comprised the study group. These patients were further grouped
with regards to their age, course of the disease, mode of diabetic management,
glycemic control, presence / absence of comorbidities (present of heart disease
and hypertension) and presence / absence of diabetic complications (diabetic
retinopathy, diabetic neuropathy and diabetic nephropathy).
Table No. 9: Age Distribution
Patients were distributed across the age spectrum of 40 to 78 years. Mean age of
the patients was 58.30 years. Most patients (n=36) were in the age group of 51-
60 years. Youngest patient was 38 years old.
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Table: 8 Age Distribution
Graph 1: Age Distribution
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Table 9: Characteristics of study population
SI.No Characteristics of population values
1. No of people examined 100
2. Age in years 58.3(40-78)
3. Men 67
4. Women 33
5. Duration of diabetes 5.5(01-22)
MEDICATION
6. Insulin 05
7. Oral Hypoglycemics 69
8. Insulin and oral
hypoglycemic
26
9. Diet only 00
Co morbidities
10. Hypertension 32
Diabetic retinopathy 37
Page | 80
11. Non proliferative diabetic
retinopathy
33
Proferative retinopathy 04
Diabetic nepharopathy 18
Microaibumineria 15
Macroalbumineria 03
CHARACTERISTICS
The average duration of diabetes in study population was 5.5
years and range was 1 year to 22 years. As for the mode of diabetic treatment, 5
patients received only insulin, 69 patients only oral hypoglycemic agents and 26
patients received both. 32 patients had hypertension and 16 patients had
ischemic heart disease and 56 patients had no comorbidities. Total 37 patients
had diabetic retinopathy and out of them, 33 had nonproliferative diabetic
retinopathy and 4  had proliferative diabetic retinopathy.. 18 patients had
diabetic nephropathy; 15 had microalbuminuria (30 – 299 mg/d) and 3 had
clinical proteinuria (> 300 mg/d). 68 patients were found to have poor glycemic
control defined as HbA1C > 7%
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Table10: Prevalence of hypomagnesmia in study population
Sl.No Sex No. ofPatients Hypomagnesimia Percentage
1 Male 67 19 28.4
2 Female 33 12 36.4
Total 100 31 31
PREVALNCE OF HYPO MAGNESEMIA
31, 31%
69, 69%
Hypomagnesemia
Non Hypomagnesemia
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Table:11 Prevalence of Hypomagnesemia and Duration of diabetes
Hypomagnesemia (defined as fasting serum magnesium concentration < 1.7
mg/dl) was found in 31 patients. 69 patients had normomagnesemia. No
patient had hypermagnesemia.
No significant difference was found in the rate of hypomagnesemia in
men and women (28.40% and 36.40% respectively). Mean serum magnesium
concentrations were also similar in men and women.
Sl.No
Duration of
Diabetes
No.of
Patients
Hypomagnesemia
patients
%
Distribu
tion
1 0-5 47 14 29.8
2 6:10 25 8 32
3 11:15 17 7 41.2
4 16:20 9 1 11
5 >20 2 1 50
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Graph: 3
The average course of the disease was 5.5 years (01-22 years). The chi-square (
χ2) value is 0.769 and P value is 0.586 at 4 degrees of freedom. So the
correlation is insignificant at P value 0.05. So, the duration of diabetes did not
significantly predict serum magnesium concentration
Table 12: Prevalence of hypomagnesemia and mode of diabetic treatment
Treatment No of patients Hypomagnesemia % distribution
Insuline treated 34 11 32.35
Non insuline treated 66 20 30.3
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Graph: 4
Hypomagnesemia
A higher prevalence of hypomagnesemia was observed in patients treated
with insulin. However, the difference was statistically insignificant. χ2 value of
0.033 and P value of 0.855 at degree of freedom 1.
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PREVALENCE OF HYPOMAGNESEMIA AND FASTING BLOOD SUGAR
Table 13:
FBS No. ofPatients Hypomagnesemia
%
Distribution
<90 6 1 14.29
91-100 15 3 20
101-110 21 2 9.51
111-120 20 8 40
121-130 16 7 43.75
>130 22 10 45.45
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Table 14: PREVALENCE OF HYPOMAGNESEMIA AND HbA1C
Graph:6
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Hypomagnesemia
Serum magnesium concentration showed no significant correlation with
fasting blood sugars or with HbA1C, though a higher prevalence of
hypomagnesemia was found with higher fasting sugar (> 130 mg%) and
Hb1AC
(> 7%). For FBS, χ 2 = 10.412, P = 0.064, DF= 5 and for Hb1AC, χ2 =
9.728, P = 0.083 and DF=5.
PREVALENCE OF HYPOMAGNESEMIA AND DIABETIC
RETINOPATHY
Table 15
Retinopathy
No. of
Patients
Hypomagnesemia
Normo
Normomagnesemi
a
NPDR 33 16 17
PDR 5 3 2
Total 38 19 19
Non Retinopathy 62 13 12
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Observations revealed a definite correlation between hypomagnesemia
and diabetic retinopathy. Patients with diabetic retinopathy had a significantly
higher prevalence of hypomagnesemia compared to patients without
retinopathy (51.30% v/s 19.00%) and more over patients who had retinopathy
were found to have lower mean serum magnesium level than those without
retinopathy(17.4mg/dl v/s 18.2 mg/dl). The difference was statistically
significant ( χ2 value 9.911 and P value 0.002 (< 0.05) at degree of freedom 1).
PREVALENCE OF HYPOMAGNESEMIA AND
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Table16: PREVALENCE OF HYPOMAGNESEMIA AND DIABETIC
NEPHAROPATHY
Nephropathy No.ofPatients
Hypo
magnesemia
Normo
magnesemia
Nephropathy
Microalbuminuria 14 4 28.57
Macroalbuminuria 5 1 20
Total 19 5 26.32
Non Nephropathy 81 26 32.1
The difference in prevalence rates of hypomagnesemia in patients with
nephropathy and without nephropathy had no statistical significance
( χ2=0.106, P = 0.744, DF=1).
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TABLE: 17 PREVALENCE OF HYPOMAGNESEMIA AND
HYPERTENSION
HTN No. ofPatients Hypomagnesemia
% of
Distribution
HTN 34 8 23.53
No HTN 66 23 34.85
Graph:9
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Table: 18. PREVALENCE OF HYPOMAGNESEMIA AND DIABETIC
COMPLICATIONS
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38 18 47.36
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Prevalence of hypomagnesemia in diabetics with complications was
significantly higher compared to diabetics with no complications (45.24%
versus 20.68%). The difference was statistically significant ( χ2 value is 6.863
and P value 0.008 at DF of 1). In addition, average serum magnesium
concentration in patients with diabetic complications was relatively lower than
in diabetics without any complication (1.72 mg/dl and 1.84 mg/dl). Among the
diabetics with complications the prevalence of hypomagnesaemia was not
significantly different in groups of patients with only retinopathy, only
neptharopathy, retinopathy with nephropathy or all three complications (χ2
value is 0.8922 and P value 0.684 at DF of 3). Among the patients with
hypomagnesemia, prevalence rate of hypertension, diabetic nephropathy and
poor glycemic indices were comparable to normomagnesemic group. However,
conclusively higher prevalence of diabetic retinopathy was found in
hypomagnesemic patients compared to normomagnesemics (61.30% versus
26.00%).
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DISCUSSION
Widespread presence of low level of serum magnesium noted, among
these patients and presence of association between hypomagnesemia and
diabetic complications elicitable from this study.
Severe  magnesium deficiency has been  noticed in the previous studies in
patients with type-2 diabetes. , some workers have also reported high and even
low levels. In the present study, serum magnesium concentrations of 31 patients
with type 2 diabetes, were below the reference range. This confirms to the
reported the presence  of low plasma magnesium status in type-2 diabetics in
many studies, which are ranged from 26 to 38%. Prevalence of
hypomagnesemia in type – 2 diabetics in our study was similar to that reported
by Nadler et al.5 in type 2 diabetics attending outpatient clinics in the US. Walti
MK et al. also reported a prevalence of hypomagnesemia in type 2 diabetics
conduced  at Zurich, Switzerland 37.6% versus 10.9% in nondiabetic controls.
Magnesium is present mainly  as an intracellular cation, with less than
one persent  of total body content present in the extracellular fluids. The
magnesium concentration in serum represents less than 0.3% of total body
magnesium. however, though less sensitive presence of low level of serum
magnesium concentration , is a highly specific indicator of. In addition, serum
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magnesium measurement is the most readily available and widely used test of
magnesium status.
The reasons for the increase prevalence of magnesium deficiency in
diabetes though not clear, but may include increased  urinary  excretion, low
level of dietary intake, or decreased absorption of magnesium when compared
to healthy people. Several studies have noticed increased urinary magnesium
excretion in both type 1 and type 2 diabetes. Recently a specific tubular defect
has been noticed in magnesium reabsorption in thick ascending loop of Henle .
This defect leads to reduction in tubular reabsorption of magnesium and
produce hypomagnesemia. The reason for this tubular defect in diabetics is  not
clear.  Treatment with insulin has been shown to correct renal loss of
magnesium  in diabetics. Low dietary intake is an unlikely cause of decreased
magnesium status in diabetes. A dietary survey conducted in Germany showed
that only >6% of the diabetic group and >19% of the control group had intakes
of magnesium below their individual daily  requirements. In addition, recently it
has been shown that type 2 diabetics in reasonable metabolic control absorb
dietary magnesium to a similar extent as healthy controls. Increased urinary
magnesium excretion due to hyperglycemia and osmotic diuresis may
contribute to hypomagnesemia in diabetes.
Serum levels of magnesium have been found by several investigators to
correlate inversely with fasting blood glucose concentration72,73 and the
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percentage of HbA1C.72 Schlienger et al.7 studied the influence of glycemic
control (glycemic control evaluated by HbA1C) on various trace elements and
reported significantly reduced plasma magnesium levels in patients with poor
control of diabetes. The present study revealed no statistically significant
correlation between serum magnesium levels and fasting blood sugar and
HbA1C. However, patients with poor glycemic parameters (FBS>130 mg/dl or
79 HbA1C > 7%) had a significantly higher prevalence of hypomagnesemia
(43.4% and 35.8%) compared to over all prevalence in diabetics (31%).
Glycosylated hemoglobin (HbA1C) results from glycosylation of
hemoglobin by a reaction between glucose and N-terminal valine of beta chain
of Hb molecules. When plasma glucose is consistently elevated, there is an
increased glycosylation of hemoglobin. HbA1C assays approximate with mean
plasma glucose values over the previous 2 to 3 months. Higher percentages of
HbA1C indicate poor glycemic control in the previous months.
Hypomagnesemia is reported to be both a cause and result of poor
glycemic control. Magnesium is a cofactor in both glucose transporting
mechanisms of cell membrane and various enzymes important in carbohydrate
oxidation.4 In addition, magnesium deficiency has been shown to promote
insulin resistance in multiple studies. Nadler et al.8 have reported that insulin
sensitivity decreases even in nondiabetic individuals after induction of
magnesium deficiency. Like wise, elderly subjects were shown to have
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improved glucose tolerance when they received magnesium supplements. Thus
hypomagnesemia by itself results in poor glycemic control. Conversely,
hyperglycemia and osmotic diuresis may lead to increased urinary magnesium
excretion and hypomagnesemia in diabetics. However, high prevalence of
hypomagnesemia is reported in type – 2 diabetics with good glycemic control.5
So, although poor glycemic control is associated with magnesium deficiency, it
is not simply induced by hyperglycemia and is not corrected by improvement in
metabolic control alone.
Sex, age and duration of diabetes were not the significant predictors of
serum magnesium levels. Yajnick et al.72 in 1984 reported that among diabetics
plasma magnesium concentration was directly related to age and men had
significantly higher concentrations than women. The increasing magnesium
levels with age were probably due to impaired renal function and the sample
size was relatively small to confirm male preponderance. In our study, patients
with impaired renal functions were excluded. Our results confirm to the recent
reports that have not shown any significant associations between sex, age and
duration of diabetes with serum magnesium levels.
Significant differences, in serum magnesium concentrations have been
reported between the insulin treated and non-insulin treated diabetics. Yajnik et
al.72 reported that insulin treated diabetics have significantly lower serum
magnesium levels compared to non insulin treated ones. In the present study
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prevalence of hypomagnesemia in insulin treated diabetics was higher than in
noninsulin treated (32.2% v/s 30.4%). However, the difference was statistically
not significant. Walti MK et al have reported that diabetes treatment (insulin or
OHA) did not significantly effect hypomagnesemia. Redistribution of
magnesium from plasma in to red blood cells is caused by insulin. In a recent
study Alzaida et al. have found that cellular uptake of magnesium is normally
stimulated by insulin. So insulin treatment may enhance cellular magnesium
uptake and result in increased prevalence of hypomagnesemia.
Studies have associated lower serum levels of serum magnesium with
higher risk of coronary artery disease. As part of Atherosclerosis risk in
communities study, a cohort of 15,792 people were observeseven  over 7 years
and  they found that an increasing relative risk of coronary artery disease with
decreasing serum magnesium has been reported.53
How a low serum magnesium predisposes to coronary artery diseases is
not known.  In the present study, no difference in prevalence of
hypomagnesemia was found between those with ischemic heart disease and
others. Similarly, no difference in prevalence of hypomagnesemia was found
between the hypertensive and non hypertensive subjects.
Previously magnesium deficiency has been found to be associated with
diabetic microvascular disease. In the present study too significantly higher
prevalence  low serum magnesiumwas observed in diabetics with microvascular
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complications and average serum concentration of magnesium in diabetics with
microvascular complications was relatively lower than in diabetics with no
microvascular complications and healthy people.
Hypomagnesemia has been reported in patients with diabetic
retinopathy, with lower magnesium levels predicting a greater risk of severe
diabetic retinopathy. Our observations  prompted  a definite association between
diabetic retinopathy and low  serum magnesium levels. There was a significant
difference is prevalence of hypomagnesemia in diabetics with retinopathy and
without retinopathy (51.3% vs 19%; P< 0.005). These observations are similar
to other reports. The mechanism by which hypomagnesemia predisposes to
diabetic retinopathy is not clear. Grafton et al. have proposed the inositol
transport theory may  to explain this association. But the exact reason remains
unknown.
With reference to other diabetic microangiopathies, no significant
association was found between prevalence of hypomagnesemia, d and diabetic
nephropathy. Even within the nephropathy group, no difference was found
between patients with microalbuminuria and macroalbuminuria. These results
are similar to those reported by Pickup et al. who found no difference in serum
magnesium concentrations between diabetics with microalbuminuria or clinical
proteinuria compared to diabetics with normal albumin excretion. In contrast,
Corsonello, et al demonstrated significantly lower serum magnesium in type 2
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diabetics with nephropathy compared to a normoalbuminemic group. They
argued that in diabetics with nephropathy, serum magnesium might be reduced
because of lower serum albumin concentration, as 30% of serum magnesium is
bound to proteins, mainly albumin. In our study, 15 patients had
microalbuminuria and 3  patients who had macroalbuminuria had 24 hour
albumin excretion less than 1.5 mg. This should not lower plasma albumin,
because plasma contains macro-amounts (35-52 g/L) of albumin.
In summary, the present study has demonstrated that hypomagnesemia is
common in type 2 diabetics and magnesium deficiency is conclusively
associated with diabetic retinopathy. So it may be prudent in clinical practice to
periodically monitor plasma magnesium concentrations in diabetic patients. If
plasma 83 magnesium is low, an intervention to increase dietary intakes of
magnesium may be beneficial.
CONCLUSION
• Prevalence of hypomagnesemia in type 2 diabetics is 30%.
• Prevalence of hypomagnesemia is significantly higher in patients with
microvascular diabetic complications compared to diabetics with no
complications.
• Hypomagnesemia is significantly associated with diabetic retinopathy.
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• No significant association exists between glycemic control, other diabetic
microangiopathies (nephropathy and neuropathy) and diabetic comorbidities –
ischemic heart disease and hypertension.
SUMMARY
Present study was conducted to estimate the prevalence of
hypomagnesaemia in type 2 diabetics and to study the possible association of
hypomagnesaemia with diabetic complications  like retinopathy and
nephropathy .
The study included 100 people with type 2 diabetics, with no factors
significantly altering the serum magnesium levels. Fasting serum magnesium
levels were taken and correlated with glycemic control and diabetic
complications.
The results demonstrated prevalence of hypomagnesaemia in type 2
diabetics as 31% and magnesium deficiency was conclusively associated with
diabetic retinopathy. No significant associations were found between serum
magnesium levels and other variables – duration of diabetes, glycemic control,
mode of diabetic treatment, diabetic nephropathy and hence it is prudent in
clinical practice to periodically monitor plasma magnesium concentrations in
diabetic patients. If plasma magnesium is low, an intervention to increase
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dietary intakes of magnesium rich foods may be beneficial. However, the role of
magnesium supplements remains to be evaluated.
ANNEXURE I – PROFORMA
Serial No. :
Patient Details Name :
Hospital No. :
Age:
Sex:
Occupation:
Diabetic History
Age of onset :
Total Duration :
Mode of Treatment
1. Oral hypoglycemic agents : (Suplhanylurea/biguanide)
2. Insulin (Type) :
3. Diabetic Diet :
Symptoms Related to Complications
Symptoms of Nephropathy
• Oliguria :
• Oedema :
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Symptoms of Retinopathy
• Dimness of vision : • Blindness :
Past History
• IHD: • HTN:
Family History
• DM: • IHD: • HTN:
Examination
Height:  Weight:  General Examination: Pulse Rate: Edema:
BP:  Supine: Standing:
C. Eye Signs
• Diabetic retionopathy : o Non Proliferative :  Proliferative :
D. Signs of nephropathy
• Oedema: • Facial puffiness :
E. Cardiovascular system F. Respiratory system G. Per abdomen
Investigations
1. FBS:  PPBS:  HbA1C :
2. Serum Magnesium: 3. 24 hour albuminiuria:
4. Urea: Creatinine: 5. Routine Urine: Sugar: Protein: Microscopy:
6 ECG: 7 Others:
DATA ON SERUM MAGNESIUM LEVEL IN TYPE 2 DIABETES AND CORREALTION WITH DIABETIC RETINOPATHY AND  NEPHROPATHY
Sl
No Name Age Sex Occu
IP/
OP DOI Drugs
Wt
(kg)
Ht
(m) BMI SBP DBP FBS HbA1C S.Mg U-Pro Urea S.C LP NPDR PR
1 THANGAM 51 F S OP 5 OHA 45 1.39 23.29 126 82 141 8 1.6 <300 36 1 N N Nil
2 THAYEE 58 F S OP 6 OHA 56 1.55 23.31 130 92 136 7 1.6 >300 35 1.1 HL N NIL
3 SUSEELA 49 F NS OP 3 OHA 78 1.58 31.24 140 80 128 6.5 1.7 <300 35 1 N N NIL
4 MEENA 43 F NS OP 1 OHA 64 1.62 24.39 126 84 118 6 1.8 <300 28 1.2 HL N NIL
5 PANJALI 60 F S OP 10 OHA 65 1.57 26.37 156 90 130 8 1.6 >300 36 1.2 HL P NIL
6 RANI 57 F S OP 9 OHA 75 1.52 32.46 138 90 142 9 1.6 <300 34 1.2 HL P NIL
7 KANNAN 65 M S OP 8 OHA 76 1.64 29.74 150 100 136 9 1.5 >300 40 1.8 HL N NIL
8 GOPAL 65 M NS OP 10 OHA+INJ 76 1.58 32.89 140 92 126 7 1.6 <300 36 1 HL P NIL
9 JAYARAM 69 M S OP 6 OHA 80 1.64 10.02 140 90 132 8 1.6 <300 28 1.1 HL N NIL
10 GANGA 61 F S OP 5 OHA 65 1.42 32.23 140 90 128 10 1.6 <300 36 1.2 HL N NIL
11 AMUDHA 50 F NS OP 3 OHA 61 1.6 23.82 130 90 116 7 1.7 <300 36 1.2 N N NIL
12 SUNDHARI 74 F S OP 12 OHA 60 1.63 22.58 140 90 122 7 1.9 <300 32 1.2 N N NIL
13 VIJAYA 42 F NS OP 2 OHA 75 1.64 27.81 130 80 126 7 1.8 <300 36 1 N N NIL
14 BHAI 45 M NS OP 3 OHA 95 1.71 32.49 140 90 132 8 1.8 <300 36 1.2 HL N NIL
15 CHANDRA 39 F NS OP 1 OHA 50 1.52 21.64 130 80 120 6.5 2 <300 32 1.1 N N NIL
16 THAMBI 61 M S OP 8 OHA 59 1.65 25.71 126 92 126 9 1.7 <300 36 1 N P NIL
17 SURYA 55 F NS IP 6 OHA 65 1.7 26.1 122 86 135 10 1.5 >300 36 1.2 N N NIL
18 BANU 59 F NS OP 8 OHA 67 1.49 30.17 130 82 140 11 1.6 >300 38 1.4 N N NIL
19 DURAI 64 M NS OP 10 OHA 65 1.42 32.25 140 90 130 12 1.4 >300 36 1.2 HL N NIL
20 MANI 52 M NS OP 6 OHA 79 1.72 27.33 140 90 136 10.5 1.6 <300 35 1 N N NIL
21 RAJENDREN 58 M NS OP 8 OHA 62 1.58 24.83 138 92 219 10 1.7 <300 36 1.2 N N NIL
22 CHELLAM 75 M S OP 10 OHA 56 1.62 21.21 150 90 225 9 1.6 >300 38 1.2 N P NIL
23 JANAKI 54 F NS OP 4 OHA 66 1.5 29.33 152 90 223 11 1.6 >300 38 1.2 N P NIL
24 RUBY 60 F NS OP 10 OHA 62 1.6 24.21 100 80 98 6 1.9 <300 32 0.9 N N NIL
25 CHANDRA 67 F NS OP 6 OHA 68 1.7 28.52 128 90 83 6 1.6 <300 30 1 N N NIL
26 MANO 38 M NS OP 1 OHA 86 1.65 31.59 130 80 240 9 1.6 <300 29 1.2 N N NIL
27 RAJU 64 M NS OP 6 OHA 72 1.78 26.37 150 90 180 10 1.6 >300 40 1 N N NIL
28 PAKARI 59 M S OP 5 OHA 78 1.65 28 150 90 250 11 1.5 <300 42 2.1 N P NIL
29 SAMI 64 M NS OP 7 OHA 82 1.68 29 138 86 164 9 1.7 <300 30 1.2 N N NIL
30 THIRU 50 M NS IP 3 OHA 65 1.69 32 140 90 118 7 1.9 <300 30 1.2 N N NIL
31 RAMESH 38 M NS OP 3 OHA+INJ 68 1.65 23 120 80 148 10 1.5 >300 40 2.5 N P NIL
32 PANDU 42 M NS OP 5 OHA+INJ 70 1.78 22 120 80 98 6.5 1.8 <300 32 1 N N NIL
33 PAVUNU 67 F S OP 5 OHA 68 1.53 29.5 140 90 145 11 1.6 >300 36 1.1 N N NIL
34 BEEBEE 58 F NS OP 8 OHA+INJ 69 1.55 28.72 138 80 185 9 1.6 >300 36 1.2 N P NIL
35 USMAN 63 M NS OP 11 OHA 72 1.61 27.78 130 80 165 11 1.7 >300 38 1.2 N P NIL
36 LATHA 60 F NS OP 9 OHA+INJ 69 1.58 27.65 140 90 163 9 1.7 >300 36 1.1 N N NIL
37 RANI 50 M NS OP 6 OHA 75 1.65 27.55 120 90 154 9 1.8 <300 32 1 N N NIL
38 MANJULA 49 F NS OP 3 OHA 64 1.75 20.09 120 80 100 11 1.6 <300 30 1 N N NIL
39 RAMAN 61 M NS IP 10 OHA 73 1.71 24.96 136 92 168 10 1.7 >300 38 1.2 HL P NIL
40 BALA 57 M NS OP 6 OHA 75 1.78 23.67 128 96 115 6 1.8 <300 32 1.2 N N NIL
41 MOHAN 56 M NS OP 6 OHA 75 1.48 34.24 130 80 263 11 1.6 >300 36 1.2 HL P NIL
42 KAMALA 45 F NS OP 5 OHA 68 1.63 25.59 134 83 111 9 1.8 <300 34 1 HL N NIL
43 KASTHURI 48 F NS OP 3 OHA 70 1.56 28.76 130 80 144 9 1.7 >300 36 1.6 HL N NIL
44 SUMAN 69 M NS OP 11 OHA 69 1.56 27.99 110 82 121 8 1.8 <300 32 1.2 N N NIL
45 KATTAN 52 M NS OP 6 OHA&INJ 78 1.58 34.67 110 78 148 9 1.6 >300 36 1.2 HL N NIL
46 PICHAI 70 M S OP 10 OHA 70 1.69 24.51 148 82 105 6 1.7 <300 32 1 N N NIL
47 NEELA 71 F S OP 9 OHA 65 1.55 27.06 136 88 128 7.5 2 <300 36 1 N P NIL
48 THULASI 48 F NS OP 5 OHA 64 1.67 22.95 140 78 132 8 1.9 <300 34 1.1 N N NIL
49 ARUMUGAM 50 M NS IP 5 OHA&INJ 76 1.69 26.61 130 82 152 9 1.7 >300 36 1.2 HL NI NIL
50 MURUGAN 48 M NS OP 4 OHA 85 1.71 29.07 140 94 252 9.5 1.6 <300 35 1.1 HL P NIL
51 KRISHNAN 55 M NS OP 5 OHA 80 1.75 26.12 132 82 152 10 1.9 <300 33 1 N N NIL
52 BABU 38 M NS OP 1 OHA 79 1.8 24.38 128 88 150 8.5 1.9 <300 34 1.1 N N NIL
53 THAYALAN 39 M NS OP 1 OHA 70 1.74 23.12 124 80 126 8 1.7 <300 36 1 N N NIL
54 KALA 40 F NS OP 4 OHA 64 1.61 24.69 110 86 105 6.5 1.9 <300 34 1.1 N N NIL
55 MURTHY 54 M NS OP 8 OHA 73 1.78 23.04 112 82 121 7 1.6 >300 30 1.2 N N NIL
56 SASIKALA 41 F NS OP 1 OHA 65 1.63 24.4 140 90 115 8 2 <300 36 1.1 N N NIL
57 MUTHU 58 M NS OP 7 OHA 74 1.74 24.1 130 80 110 6 2 <300 35 1 N N NIL
58 RAJA 54 M NS IP 4 OHA 72 1.69 25.21 140 82 148 10 1.6 >300 40 1.8 HL P NIL
59 SELVAM 52 M NS OP 3 OHA 83 1.84 24.52 110 82 96 6 2.1 <300 36 1.1 N N NIL
60 SHEELA 58 F NS OP 8 OHA&INJ 58 1.5 25.78 120 90 92 6 2 <300 34 1 N N NIL
61 JAMEELA 52 F NS OP 6 OHA 100 1.55 41.62 140 90 223 10 1.6 >300 36 1.2 N N NIL
62 RUPA 49 F NS OP 9 OHA+INJ 95 1.65 34.89 140 90 245 10 1.6 >300 40 2 HL P NIL
63 ELLAMMAL 63 F S OP 9 OHA 65 1.51 28.51 140 80 189 10 1.6 >300 36 1 N N NIL
64 THIYAGU 70 M S OP 10 OHA 67 1.76 21.63 150 90 90 6.5 1.8 <300 28 1.2 N N NIL
65 KILLIAMMAL 69 F S OP 9 OHA+INJ 64 1.6 25 150 90 98 6 1.8 <300 28 1.2 N N NIL
66 NADHU 41 M NS OP 6 OHA 72 1.75 23.51 30 80 116 6.7 1.7 <300 32 1 N N NIL
67 PUSHA 59 F NS OP 6 OHA+INJ 69 1.57 27.99 150 90 320 11 1.5 >300 36 1.2 N N NIL
68 MURALI 51 M NS OP 5 OHA 69 1.69 24.16 140 90 236 10 1.7 >300 30 0.9 N P NIL
69 LAKSHMI 59 F NS OP 6 OHA+INJ 69 1.57 27.99 150 90 220 11 1.6 >300 38 1.2 N P NIL
70 SUNDHARI 61 F S OP 10 OHA 70 1.55 29.14 140 80 200 11 1.6 >300 30 1.7 N N NIL
71 MUNIAMMAL 65 F S IP 12 OHA 75 1.52 32.46 130 90 187 9 1.6 <300 26 1 N N Nil
72 VARADHAN 75 M S OP 15 OHA&INJ 69 1.68 24.45 140 90 210 9 1.6 >300 36 1.2 N NI NIL
73 SARASU 68 F NS OP 10 OHA 65 1.76 20.98 120 86 188 8 1.6 >300 36 1.2 N P NIL
74 MANIMEGALAI 67 F NS OP 7 OHA 62 1.58 24.84 150 90 200 11 1.5 >300 36 1.2 N P NIL
75 URLAMILA 48 F NS OP 5 OHA 68 1.6 26.54 140 90 135 7 1.8 <300 30.8 1.2 HL P NIL
76 BRINTHA 40 F NS OP 2 OHA+INJ 65 1.65 23.88 130 80 98 6 2 <300 32 1 N N NIL
77 BANU 39 F NS OP 1 OHA 60 1.62 22.86 130 90 90 6.5 2 <300 26 1 N N NIL
78 MEERA 45 F NS OP 3 OHA 65 1.59 22.79 126 86 101 7 1.7 <300 28 0.8 N N NIL
79 JAYATHI 40 F NS OP 2 OHA 60 1.63 22.58 128 78 93 6.5 2 <300 30 1 N N NIL
80 KAMATCHI 58 F S IP 5 OHA 70 1.66 25.4 130 90 98 6 1.6 <300 32 1 N N NIL
81 POOGKODI 55 F NS OP 3 OHA 65 1.59 25.71 128 78 105 7 2 <300 28 1 N N NIL
82 AMMU 45 F NS OP 2 OHA 66 1.58 26.44 126 82 110 8 2 <300 27 1 N N NIL
83 SURYA 52 M NS OP 6 OHA&INJ 68 1.52 29.43 136 88 112 8 1.7 >300 36 1.2 HL P NIL
84 VEERAN 72 M S OP 10 OHA 65 1.71 22.23 148 88 115 8.5 1.7 <300 37 1.2 N N NIL
85 RATHINAM 78 M S OP 12 OHA 78 1.65 25.86 146 90 105 7 1.7 <300 36 1.2 N N NIL
86 GOMATHI 69 F S OP 12 OHA 65 1.54 27.41 150 100 185 10 1.6 >300 36 1.2 N P NIL
87 SEETHA 65 F S OP 9 OHA 59 1.59 23.34 148 90 122 7 1.8 <300 30 1.2 N N NIL
88 MANI 41 M NS IP 1 OHA 75 1.72 22.35 120 8 110 77 1.7 <300 34 1 N N NIL
89 SRINIVAS 40 M NS OP 1 OHA 70 1.65 25.71 116 78 126 8 1.9 >300 32 1 HL N NIL
90 MOHAN RAJ 52 M NS OP 4 OHA 65 1.66 23.79 126 70 114 7 1.6 <300 32 1 N N NIL
91 DHANAM 55 M NS OP 5 OHA 56 1.67 20.08 130 80 96 6.5 2 <300 36 1.2 N N NIL
92 THIRUPATHI 60 M NS OP 6 OHA 58 1.6 23.39 150 90 89 6.6 2 <300 28 1 N N NIL
93 ARUL 42 M NS OP 3 OHA 65 1.71 25.97 140 80 100 7 1.9 <300 28 0.9 N N NIL
94 NARESH 48 M NS OP 5 OHA&INJ 70 1.73 27.6 136 80 109 7 1.8 <300 34 0.8 N N NIL
95 DILLI RANI 63 F S OP 10 OHA 60 1.52 29.22 140 90 96 7 1.6 <300 36 0.7 N N NIL
96 SIVAGAMI 65 F S OP 10 OHA 65 1.55 26.3 150 100 256 7 1.8 <300 39 1 N N NIL
97 ANJALI 67 F S IP 10 OHA 64 1.48 25.39 140 96 101 6 1.9 <300 31 1.2 N N NIL
98 SURESH 48 M NS OP 5 OHA&INJ 64 1.56 26.3 130 80 156 6 2 <300 30 1.1 N N NIL
99 MALAR 58 F NS OP 8 OHA 65 1.6 25.39 128 86 181 6.4 1.8 <300 28 0.9 N N NIL
100 KUMAR 52 M NS OP 5 OHA 73 1.68 25.86 148 90 108 6.4 1.9 <300 30 1 N N NIL
101 LEELA 55 F NS OP 4 OHA 67 1.54 28.25 130 84 121 7 1.7 >300 36 N N NIL
102 SHANMUGAM 59 M NS OP 7 OHA 72 1.63 27.1 128 80 111 6.5 1.8 <300 32 N N NIL
103 RAVI 69 M S OP 9 OHA 70 1.64 26.03 140 86 138 9 1.9 <300 34 N N NIL
104 MANNU 66 M NS OP 7 OHA 67 1.7 23.18 138 90 120 7 2 <300 30 N N NIL
105 SIVA 45 M NS OP 3 OHA 79 1.71 27.02 140 90 118 7 2 <300 32 N N NIL
106 RAMU 56 M NS OP 4 OHA 60 1.68 21.26 146 98 100 6.5 1.9 <300 31 N N NIL
107 VADAMALAI 69 M S OP 11 OHA 69 1.74 22.79 120 82 132 8 1.7 >300 32 HL P NIL
108 DHAMU 56 M NS IP 3 OHA 73 1.58 29.24 130 80 125 7.5 1.9 <300 34 N N NIL
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